<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Arzerra II-50 &amp; II-51 - PI - EN - clean</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h2
	{margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-35.4pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{margin-top:0in;
	margin-right:-.05pt;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-name:"Heading 5\, DO NOT USE";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin-top:0in;
	margin-right:4.8pt;
	margin-bottom:0in;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-link:"Caption Char";
	margin:0in;
	line-height:16.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{mso-style-link:"List Bullet 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:110%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0in;
	text-align:justify;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:77.9pt;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-35.4pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-align:justify;
	text-indent:-14.2pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-align:justify;
	text-indent:-14.2pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.CharChar1CharCharCharCharCharChar1CharCharCharCharCharChar, li.CharChar1CharCharCharCharCharChar1CharCharCharCharCharChar, div.CharChar1CharCharCharCharCharChar1CharCharCharCharCharChar
	{mso-style-name:"Char Char1 Char Char Char Char Char Char1 Char Char Char Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;}
p.listbull, li.listbull, div.listbull
	{mso-style-name:"list\:bull";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.3in;
	text-indent:-.3in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.NoNumHead4, li.NoNumHead4, div.NoNumHead4
	{mso-style-name:"NoNum\:Head4";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.NoNumHead2, li.NoNumHead2, div.NoNumHead2
	{mso-style-name:"NoNum\:Head2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.BridgeheadGDS, li.BridgeheadGDS, div.BridgeheadGDS
	{mso-style-name:"Bridgehead GDS";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.CSIchar
	{mso-style-name:CSIchar;
	border:none;
	background:#CCCCCC;}
p.Bullet, li.Bullet, div.Bullet
	{mso-style-name:Bullet;
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.55pt;
	text-indent:-14.2pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.NoNumHead3, li.NoNumHead3, div.NoNumHead3
	{mso-style-name:"NoNum\:Head3";
	mso-style-link:"NoNum\:Head3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
span.NoNumHead3Char
	{mso-style-name:"NoNum\:Head3 Char";
	mso-style-link:"NoNum\:Head3";
	font-family:"Arial",sans-serif;
	text-transform:uppercase;
	font-weight:bold;}
p.Char1CharCharCarCarChar, li.Char1CharCharCarCarChar, div.Char1CharCharCarCarChar
	{mso-style-name:"Char1 Char Char Car Car Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CharChar4CharCharChar, li.CharChar4CharCharChar, div.CharChar4CharCharChar
	{mso-style-name:"Char Char4 Char Char Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.listindentbull, li.listindentbull, div.listindentbull
	{mso-style-name:"list\:indent bull";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.6in;
	text-indent:-.3in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.tabletextNS, li.tabletextNS, div.tabletextNS
	{mso-style-name:"table\:textNS";
	mso-style-link:"table\:textNS Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Arial Narrow",sans-serif;}
span.tabletextNSChar
	{mso-style-name:"table\:textNS Char";
	mso-style-link:"table\:textNS";
	font-family:"Arial Narrow",sans-serif;}
span.LBLLevel3
	{mso-style-name:"LBLLevel 3";
	font-family:"Arial",sans-serif;
	text-decoration:underline;}
span.LBLAnnotations
	{mso-style-name:"LBL Annotations";
	color:blue;}
span.LBLTableFootnotesChar
	{mso-style-name:"LBL Table Footnotes Char";
	mso-style-link:"LBL Table Footnotes";}
p.LBLTableFootnotes, li.LBLTableFootnotes, div.LBLTableFootnotes
	{mso-style-name:"LBL Table Footnotes";
	mso-style-link:"LBL Table Footnotes Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:13.7pt;
	text-indent:-13.7pt;
	line-height:16.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.LBLBulletStyle1, li.LBLBulletStyle1, div.LBLBulletStyle1
	{mso-style-name:"LBL BulletStyle 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:16.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.LBLLevel4
	{mso-style-name:"LBLLevel 4";
	font-family:"Arial",sans-serif;
	font-style:italic;}
span.ListBullet2Char
	{mso-style-name:"List Bullet 2 Char";
	mso-style-link:"List Bullet 2";}
p.CM23, li.CM23, div.CM23
	{mso-style-name:CM23;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:13.4pt;
	margin-left:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.CM6, li.CM6, div.CM6
	{mso-style-name:CM6;
	margin:0in;
	line-height:13.0pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	mso-style-link:"Title A Char";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	mso-style-link:"Title B Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.TitleAChar
	{mso-style-name:"Title A Char";
	mso-style-link:"Title A";
	font-weight:bold;}
span.TitleBChar
	{mso-style-name:"Title B Char";
	mso-style-link:"Title B";
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-weight:bold;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-weight:bold;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CSI
	{mso-style-name:CSI;
	border:none;
	background:#BFBFBF;}
span.CaptionChar
	{mso-style-name:"Caption Char";
	mso-style-link:Caption;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.tabletextNS1
	{mso-style-name:"table\:textNS1";
	font-family:"Arial Narrow",sans-serif;}
p.Text, li.Text, div.Text
	{mso-style-name:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C";
	mso-style-link:"Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.TextChar
	{mso-style-name:"Text Char";
	mso-style-link:"Text\,Graphic\,Graphic Char Char\,Graphic Char Char Char Char Char\,Graphic Char Char Char Char Char Char Char C";
	font-family:"MS Mincho";}
p.Table, li.Table, div.Table
	{mso-style-name:"Table\,10 pt  Bold\,9 pt";
	mso-style-link:"Table Char\,10 pt  Bold Char\,9 pt Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.Legend, li.Legend, div.Legend
	{mso-style-name:Legend;
	mso-style-link:"Legend Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:1.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.LegendChar
	{mso-style-name:"Legend Char";
	mso-style-link:Legend;
	font-family:"Arial",sans-serif;}
span.TableChar
	{mso-style-name:"Table Char\,10 pt  Bold Char\,9 pt Char";
	mso-style-link:"Table\,10 pt  Bold\,9 pt";
	font-family:"Arial",sans-serif;}
p.Listlevel1, li.Listlevel1, div.Listlevel1
	{mso-style-name:"List level 1";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Nottoc-headings, li.Nottoc-headings, div.Nottoc-headings
	{mso-style-name:"Not toc-headings";
	mso-style-link:"Not toc-headings Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Nottoc-headingsChar
	{mso-style-name:"Not toc-headings Char";
	mso-style-link:"Not toc-headings";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'><b>ANNEX I</b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=X-NONE>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra 100&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra 1000&nbsp;mg concentrate for
solution for infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>2.       QUALITATIVE
 AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One ml of concentrate
contains 20&nbsp;mg of ofatumumab.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Arzerra 100&nbsp;mg concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
100&nbsp;mg of ofatumumab in 5&nbsp;ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Arzerra 1000&nbsp;mg concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each vial contains 1000&nbsp;mg of
ofatumumab in 50&nbsp;ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ofatumumab is a human monoclonal antibody
produced in a recombinant murine cell line (NS0).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Excipient with known effect</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>This medicinal product
contains 34.8&nbsp;mg sodium per 300&nbsp;mg dose, 116&nbsp;mg sodium per
1000&nbsp;mg dose and 232&nbsp;mg sodium per 2000&nbsp;mg dose.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.       PHARMACEUTICAL <span style='text-transform:
 uppercase'>form</span></span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Concentrate for solution for infusion (sterile
concentrate).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Clear</span><span
lang=EN-GB> to opalescent</span><span lang=EN-GB>, colourless to pale yellow
liquid.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.       Clinical
particulars</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Previously untreated
chronic lymphocytic </u><u><span lang=EN-GB>leukaemia</span></u><u> (CLL)</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Arzerra in combination with
chlorambucil or bendamustine is indicated for the treatment of adult patients
with CLL who have not received prior therapy and who are not eligible for
fludarabine-based therapy.</span></p>

<p class=MsoNormal><span style='color:black'>&nbsp;</span></p>

<p class=MsoNormal>See section&nbsp;5.1 for further information.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><u><span style='font-size:11.0pt'>Relapsed CLL</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>Arzerra is indicated in combination with fludarabine
and cyclophosphamide for the treatment of adult patients with relapsed CLL.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>See section&nbsp;5.1 for further information.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u>Refractory
CLL</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra</span>
is indicated for the treatment of CLL in adult patients who are refractory to
fludarabine and alemtuzumab<span lang=EN-GB style='color:black'>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>See
section&nbsp;5.1 for further information.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>4.2     Posology and method of administration</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra should be administered under the
supervision of a physician experienced in the use of cancer therapy</span> and
in an environment where full resuscitation facilities are immediately
available.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal;page-break-after:
avoid'><u><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>Monitoring</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Patients should be closely monitored during administration
of ofatumumab for the onset of infusion-related reactions, including cytokine
release syndrome, particularly during the first infusion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Pre-medication</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Patients should receive the following pre&#8209;medication
medicinal products 30&nbsp;minutes to 2&nbsp;hours prior to each Arzerra
infusion according to the following dosing schedules:</span></p>

<p class=MsoNormal>&nbsp;</p>

<h6 style='line-height:normal'><u><span lang=EN-GB>Premedication schedule for
Arzerra</span></u></h6>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=151 style='width:113.45pt;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=151 colspan=2 style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><b><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>Previously untreated CLL or relapsed CLL
  </span></b></p>
  </td>
  <td width=321 colspan=4 style='width:241.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table align=center style='margin:0in;text-align:center'><b><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Refractory CLL</span></b></p>
  </td>
 </tr>
 <tr style='height:24.8pt'>
  <td width=151 style='width:113.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Infusion number</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1 and 2</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>3 to n*</span></p>
  </td>
  <td width=66 style='width:49.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1 and 2</span></p>
  </td>
  <td width=85 style='width:63.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>3 to 8</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>9</span></p>
  </td>
  <td width=95 style='width:70.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.8pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>10 to 12</span></p>
  </td>
 </tr>
 <tr>
  <td width=151 style='width:113.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Intravenous corticosteroid (prednisolone or
  equivalent)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>50&nbsp;mg</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>0 to 50&nbsp;mg**</span></p>
  </td>
  <td width=66 style='width:49.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>100&nbsp;mg</span></p>
  </td>
  <td width=85 style='width:63.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>0 to 100&nbsp;mg**</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>100&nbsp;mg</span></p>
  </td>
  <td width=95 style='width:70.9pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>50 to 100&nbsp;mg***</span></p>
  </td>
 </tr>
 <tr>
  <td width=151 style='width:113.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Oral paracetamol (acetaminophen)</span></p>
  </td>
  <td width=473 colspan=6 style='width:354.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1000&nbsp;mg</span></p>
  </td>
 </tr>
 <tr>
  <td width=151 style='width:113.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Oral or intravenous antihistamine</span></p>
  </td>
  <td width=473 colspan=6 style='width:354.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Diphenhydramine 50&nbsp;mg or cetirizine 10&nbsp;mg
  (or equivalent)</span></p>
  </td>
 </tr>
 <tr>
  <td width=624 colspan=7 style='width:467.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Legend style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>*Up to 13&nbsp;infusions in previously untreated
  CLL; up to 7&nbsp;infusions in relapsed CLL</span></p>
  <p class=Legend style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>**Corticosteroid may be either reduced or omitted
  for subsequent infusions at the discretion of the physician, if a severe
  infusion-related adverse drug reaction (ADR) did not occur with the preceding
  infusion(s).</span></p>
  <p class=Table style='margin:0in'><span style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>***Corticosteroid may be reduced for subsequent
  infusions at the discretion of the physician, if a severe infusion-related
  ADR did not occur with the preceding infusion(s).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Posology</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Previously
untreated CLL</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For
previously untreated CLL, the recommended dosage and schedule is:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Cycle&nbsp;1: 300&nbsp;mg on day&nbsp;1 followed
1&nbsp;week later by 1000&nbsp;mg on day&nbsp;8</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Subsequent cycles (until best response or a
maximum of 12&nbsp;cycles): 1000&nbsp;mg on day&nbsp;1 every 28&nbsp;days</span>.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Each cycle lasts 28&nbsp;days and is counted from day&nbsp;1
of the cycle.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Best response is a clinical response that did not improve
with 3&nbsp;additional cycles of treatment.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Relapsed
CLL</span></u></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><span style='font-size:11.0pt'>For relapsed CLL, the recommended dosage
and schedule is:</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Cycle&nbsp;1: 300&nbsp;mg on
day&nbsp;1 followed 1&nbsp;week later by 1000&nbsp;mg on day&nbsp;8</span></p>

<p class=Text align=left style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>Subsequent cycles (up to a maximum
of 6&nbsp;cycles in total): 1000&nbsp;mg on day&nbsp;1 every 28&nbsp;days.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Each cycle lasts 28&nbsp;days and is counted from day&nbsp;1
of the cycle.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Previously
untreated CLL and relapsed CLL</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>First infusion</i></p>

<p class=MsoNormal>The initial rate of the first infusion of <span lang=EN-GB>Arzerra</span><span
lang=EN-GB> </span>should be 12<span lang=EN-GB>&nbsp;</span>ml/h. During
infusion, the rate should be increased every 30&nbsp;minutes to a maximum of
400<span lang=EN-GB>&nbsp;</span>ml/h<span style='color:black'> </span>(<span
style='color:black'>see section&nbsp;6.6</span>)<span style='color:black'>. </span><span
lang=EN-GB style='color:black'>If an infusion&#8209;related ADR is observed
during infusion, see below section Dose modification and reinitiation of
therapy after infusion&#8209;related ADRs.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Subsequent infusions</i></p>

<p class=MsoNormal>If the preceding infusion(s) has (have) been completed
without severe infusion related ADRs, the subsequent infusions can start at a
rate of 25<span lang=EN-GB>&nbsp;</span>ml/h and should be increased every
30&nbsp;minutes up to a maximum of 400<span lang=EN-GB>&nbsp;</span>ml/h (<span
style='color:black'>see section&nbsp;6.6</span>). <span lang=EN-GB
style='color:black'>If an infusion&#8209;related ADR is observed during
infusion, see below section Dose modification and reinitiation of therapy
after infusion&#8209;related ADRs.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><i><span style='font-size:11.0pt'>Dose modification and reinitiation of
therapy after infusion-related ADRs</span></i></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>In the event of a mild or moderate ADR, the infusion
should be interrupted and restarted at half of the infusion rate at the time of
interruption once the patients condition is stable. If the infusion rate had
not been increased from the starting rate of 12&nbsp;ml/hour prior to
interrupting due to an ADR, the infusion should be restarted at
12&nbsp;ml/hour, the standard starting infusion rate. The infusion rate can
continue to be increased according to standard procedures, to physician
discretion and to patient tolerance (not to exceed doubling the rate every
30&nbsp;minutes).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>In the event of a severe ADR, the infusion should be
interrupted and restarted at 12&nbsp;ml/hour when the patients condition is
stable. The infusion rate can continue to be increased according to standard
procedures, to physician discretion and to patient tolerance (not to exceed
increasing the rate every 30&nbsp;minutes).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;layout-grid-mode:line'>Arzerra should be permanently
discontinued in patients who develop an anaphylactic reaction to the medicinal
product.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Refractory CLL</u></i></p>

<p class=MsoNormal style='page-break-after:avoid'>The recommended dose <span
lang=EN-GB>and schedule </span>is <span lang=EN-GB>12&nbsp;doses administered as
follows:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><s><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></s>300&nbsp;mg on day&nbsp;1 followed 1&nbsp;week later by</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><s><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></s>2000&nbsp;mg weekly for <span lang=EN-GB>7&nbsp;doses
(infusions&nbsp;2 to 8)</span> followed 4&#8209;5&nbsp;weeks later by</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><s><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></s>2000&nbsp;mg every 28&nbsp;days for 4&nbsp;doses <span
lang=EN-GB>(infusions&nbsp;9 to 12)</span></p>

<p class=Nottoc-headings style='margin:0in;page-break-after:auto'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i>First and second infusions</i></p>

<p class=MsoNormal>The initial rate of the first and second infusion of <span
lang=EN-GB>Arzerra</span> should be 12&nbsp;ml/hour. During infusion, the rate
should be increased every 30&nbsp;minutes to a maximum of 200<span lang=EN-GB>&nbsp;</span>ml/hour<span
style='color:black'> (see section&nbsp;6.6). If an infusion-related ADR is
observed during an infusion, see below section Dose modification and
reinitiation of therapy after infusion-related ADRs.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Subsequent infusions</i></p>

<p class=MsoNormal>If the preceding infusion(s) has (have) been completed
without severe infusion-related ADRs, the subsequent infusions can start at a
rate of 25&nbsp;ml/hour and should be increased every 30&nbsp;minutes up to a
maximum of 400&nbsp;ml/hour <span lang=EN-GB>(see section&nbsp;6.6)</span>. If
an infusion-related ADR is observed during an infusion, see below section Dose
modification and reinitiation of therapy after infusion-related ADRs.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Dose modification and
reinitiation of therapy after infusion-related ADRs</i></p>

<p class=MsoNormal>I<span style='color:black'>n the event of a mild or moderate
ADR, the infusion should be interrupted and restarted at half of the infusion
rate at the time of interruption, once the patients condition is stable. If
the infusion rate had not been increased from the starting rate of
12&nbsp;ml/hour prior to interrupting due to an ADR, the infusion should be
restarted at 12&nbsp;ml/hour, the standard starting infusion rate. The infusion
rate</span> can continue to be increased according to standard procedures, to
physician discretion and to patient tolerance (not to exceed doubling the rate
every 30&nbsp;minutes).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In the event of <span style='color:black'>a severe ADR, the
infusion should be interrupted and restarted at 12&nbsp;ml/hour, once the
patients condition is stable. The infusion rat</span>e can continue to be
increased according to standard procedures, to physician discretion and to patient
tolerance (not to exceed increasing the rate every 30&nbsp;minutes).</p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt;layout-grid-mode:line'>Arzerra should be permanently
discontinued in patients who develop an anaphylactic reaction to the medicinal
product.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Special populations</u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='layout-grid-mode:line'>Paediatric</span></i><i><span style='layout-grid-mode:
line'> population</span></i></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>The safety and efficacy
of Arzerra in children aged below 18&nbsp;years have not been established.
Arzerra is therefore not recommended for use in this patient population.</span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='layout-grid-mode:
line'>Elderly</span></i></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>No substantial
differences related to age were seen in safety and efficacy (see
section&nbsp;5.1). Based on available safety and efficacy data in the elderly,
no dose adjustment is required (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='layout-grid-mode:
line'>Renal impairment</span></i></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>No formal studies of
Arzerra in patients with renal impairment have been performed. No dose
adjustment is recommended for mild to moderate renal impairment </span><span
lang=EN-GB style='layout-grid-mode:line'>(creatinine</span><span
style='layout-grid-mode:line'> clearance &gt;30&nbsp;ml/min) (see
section&nbsp;5.2).</span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span style='layout-grid-mode:
line'>Hepatic impairment</span></i></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>No formal studies of </span><span
lang=EN-GB>Arzerra</span><span style='layout-grid-mode:line'> in patients with
hepatic impairment have been performed. </span><span lang=EN-GB>H</span><span
lang=EN-GB>owever, patients with hepatic impairment are unlikely to require
dose modification </span><span lang=EN-GB>(see section&nbsp;5.2)<i>.</i></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Method of administration</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra is for intravenous infusion and
must be diluted prior to administration. </span><span lang=EN-GB>For
instructions on dilution of the medicinal product before administration, </span><span
lang=EN-GB style='color:black'>s</span><span lang=EN-GB>ee section&nbsp;6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b>4.3     Contraindications</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Hypersensitivity to ofatumumab or to any of
the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Infusion-related
reactions</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous ofatumumab has been associated
with infusion-related reactions. These reactions may result in temporary
interruption or withdrawal of treatment. Pre-medication attenuates
infusion-related reactions but these may still occur, predominantly during the
first infusion. </span><span lang=EN-GB>Infusion</span><span lang=EN-GB>-related</span><span
lang=EN-GB> reactions may include, but are not limited to, anaphylactoid
events, bronchospasm, cardiac events (e.g. myocardial ischaemia/infarction,
bradycardia), chills/rigors, cough, cytokine release syndrome, diarrhoea,
dyspnoea, fatigue, flushing, hypertension, hypotension, nausea, pain, pulmonary
oedema, pruritus, pyrexia, rash, and urticaria. In rare cases, these reactions
may lead to death. </span><span lang=EN-GB>Even with pre-medication, severe
reactions, including cytokine release syndrome, have been reported following use
of ofatumumab. In the event of a severe infusion-related reaction, the infusion
of Arzerra must be interrupted immediately and symptomatic treatment instituted
(see section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>If an anaphylactic reaction occurs, Arzerra should be
immediately and permanently discontinued and appropriate medical treatment
should be initiated.</span></p>

<p class=MsoNormal><span class=CSIchar><span lang=EN-GB style='border:none'>&nbsp;</span></span></p>

<p class=MsoNormal><span lang=EN-GB>Infusion</span><span lang=EN-GB>-related</span><span
lang=EN-GB> reactions occur predominantly during the first infusion </span><span
lang=EN-GB>and tend to decrease with subsequent infusions. </span><span
lang=EN-GB>Patients with a history of decreased pulmonary function may be at a
greater risk for pulmonary complications from severe reactions and should be
monitored closely during infusion of Arzerra.</span></p>

<p class=MsoNormal><span class=CSIchar><span lang=EN-GB style='border:none'>&nbsp;</span></span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tumour
lysis syndrome</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with CLL, tumour lysis syndrome
(TLS) may occur with use of Arzerra. Risk factors for TLS include a high tumour
burden, high concentrations of circulating cells (&#8805;25,000/mm<sup>3</sup>),
hypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and
elevated lactate dehydrogenase levels. Management of TLS includes correction of
electrolyte abnormalities, monitoring of renal function, maintenance of fluid
balance and supportive care.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Progressive
multifocal leukoencephalopathy</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Cases of progressive
multifocal leukoencephalopathy (PML) resulting in death have been reported in CLL
patients receiving cytotoxic pharmacotherapy, including ofatumumab. A diagnosis
of PML should be considered in any Arzerra patient who reports the new onset of
or changes in pre-existing neurological signs and symptoms. If a diagnosis of
PML is suspected Arzerra should be discontinued and referral to a neurologist
should be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Immunisations</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety of, and ability to generate a
primary or anamnestic response to, immunisation with live attenuated or
inactivated vaccines during treatment with ofatumumab has not been studied. The
response to vaccination could be impaired when B-cells are depleted. </span>Due
to the risk of infection, administration of live attenuated vaccines should be
avoided during and after treatment with ofatumumab, until B-cell counts are normalised.<span
lang=EN-GB> The risks and benefits of vaccinating patients during Arzerra
therapy should be considered.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatitis
B</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Hepatitis B virus (HBV) infection and
reactivation, in some cases resulting in fulminant hepatitis, hepatic failure
and death, has occurred in patients treated with medicinal products classified
as CD20-directed cytolytic antibodies, including Arzerra. Cases have been
reported in patients who are hepatitis B surface antigen (HBsAg) positive and
also in those who are hepatitis B core antibody (anti-HBc) positive but HBsAg
negative. Reactivation has also occurred in patients who appear to have
resolved hepatitis B infection (i.e. HBsAg negative, anti-HBc positive, and
hepatitis B surface antibody [anti-HBs] positive).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>HBV reactivation is defined as an abrupt
increase in HBV replication manifesting as a rapid increase in serum HBV DNA
level or detection of HBsAg in a person who was previously HBsAg negative and
anti-HBc positive. Reactivation of HBV replication is often followed by
hepatitis, i.e. increase in transaminase levels and, in severe cases, increase
in bilirubin levels, liver failure, and death.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients should be screened for HBV
infection by measuring HBsAg and anti-HBc before initiation of Arzerra
treatment. For patients who show evidence of prior (HBsAg negative, anti-HBc
positive) hepatitis B infection, physicians with expertise in managing
hepatitis B should be consulted regarding monitoring and initiation of HBV
antiviral therapy. Arzerra treatment should not be initiated in patients with
evidence of current hepatitis B infection (HBsAg positive) until the infection
has been adequately treated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with evidence of prior HBV
infection should be monitored for clinical and laboratory signs of hepatitis or
HBV reactivation during treatment with and for 6&#8209;12&nbsp;months following
the last infusion of Arzerra. HBV reactivation has been reported up to
12&nbsp;months following completion of therapy. Discontinuation of HBV
antiviral therapy should be discussed with physicians with expertise in
managing hepatitis B.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients who develop reactivation of HBV
while receiving Arzerra, Arzerra and any concomitant chemotherapy should be
interrupted immediately, and appropriate treatment instituted. Insufficient
data exist regarding the safety of resuming Arzerra in patients who develop HBV
reactivation. Resumption of Arzerra in patients whose HBV reactivation resolves
should be discussed with physicians with expertise in managing hepatitis B.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Cardiovascular</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with a history of cardiac disease
should be monitored closely. </span><span lang=EN-GB>Arzerra should be
discontinued in patients who experience serious or life-threatening cardiac
arrhythmias.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black;border:none windowtext 1.0pt;
padding:0in'>The effect of multiple doses of Arzerra on the QTc interval was
evaluated in a pooled analysis of three open-label studies in patients with CLL
(N=85</span><span style='border:none windowtext 1.0pt;padding:0in'>). </span><span
style='border:none windowtext 1.0pt;padding:0in'>Increases above 5&nbsp;msec
were observed in the median/mean QT/QTc intervals in the pooled analysis.<span
style='color:red'> </span></span><span style='color:black;border:none windowtext 1.0pt;
padding:0in'>No large changes in the mean QTc interval (i.e.
&gt;20&nbsp;milliseconds) were detected. None of the patients had an increase of
QTc to &gt;500&nbsp;msec. A concentration-dependent increase in QTc was not
detected. It is recommended that patients have electrolytes such as potassium
and magnesium measured prior to and during the administration of ofatumumab.
Electrolyte abnormalities should be corrected. The effect of ofatumumab on
patients with prolonged QT intervals (e.g. acquired or congenital) is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Bowel
obstruction</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Bowel obstruction has been reported in
patients receiving anti-CD20 monoclonal antibody therapy, including ofatumumab.
Patients who present with abdominal pain, especially early in the course of
ofatumumab therapy, should be evaluated and appropriate treatment instituted.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Laboratory
monitoring</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Cytopenias, including prolonged and
late-onset neutropenia, have been reported during ofatumumab therapy. Complete
blood counts, including neutrophil and platelet counts, should be obtained at
regular intervals during Arzerra therapy and more frequently in patients who
develop cytopenias.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Sodium
content</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>This medicinal product
contains 34.8&nbsp;mg sodium per 300&nbsp;mg dose, 116&nbsp;mg sodium per
1000&nbsp;mg dose and 232&nbsp;mg sodium per 2000&nbsp;mg dose.</span><b><i><span
lang=EN-GB style='color:navy'> </span></i></b><span lang=EN-GB
style='color:black'>This should be taken into consideration by patients on a
controlled sodium diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5     Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Although limited formal drug-drug
interaction data exist for </span><span lang=EN-GB>ofatumumab</span><span
lang=EN-GB>, there are no known clinically significant interactions with other
medicinal products. </span><span lang=EN-GB>No clinically relevant
pharmacokinetic interactions were observed between </span><span lang=EN-GB>ofatumumab</span><span
lang=EN-GB> and fludarabine, cyclophosphamide,bendamustine, chlorambucil, or
its active metabolite, phenylacetic acid mustard.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Live attenuated or inactivated vaccine
efficacy may be impaired with ofatumumab. Therefore, the concomitant use of
these agents with ofatumumab should be avoided. </span><span lang=EN-GB>If the
coadministration is judged unavoidable, the risks and benefits of vaccinating
patients during therapy with </span><span lang=EN-GB>ofatumumab </span><span
lang=EN-GB>should be considered (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.6     </span></b><b><span
lang=EN-GB>Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Women of
child-bearing potential</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Since
ofatumumab may cause foetal B-cell depletion, effective contraception (methods
that result in less than 1% pregnancy rates) has to be used during Arzerra therapy
and for 12&nbsp;months after the last Arzerra dose. After this period, planning
of a pregnancy in relation to the underlying disease, should be evaluated by
the treating physician.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Ofatumumab may cause foetal B-cell
depletion based on findings from animal studies and on its mechanism of action
(see section&nbsp;5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There are no adequate and well-controlled
studies in pregnant women to inform a product-associated risk. No
teratogenicity or maternal toxicity were observed in an animal reproduction
study with administration of ofatumumab to pregnant monkeys (see
section&nbsp;5.3). Ofatumumab should not be administered to pregnant women
unless the possible benefit to the mother outweighs the possible risk to the
foetus.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Administration of live vaccines to neonates
and infants exposed to ofatumumab <i>in utero</i> should be avoided until
B-cell recovery occurs (see sections&nbsp;4.4 and 4.5).</span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=Nottoc-headings style='margin:0in'><u><span style='font-size:11.0pt;
font-family:"Times New Roman",serif;font-weight:normal'>Breast-feeding</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>It is unknown whether Arzerra is excreted
in human milk, however human IgG is secreted in human milk. The safe use of
ofatumumab in humans during lactation has not been established. The excretion of
ofatumumab in milk has not been studied in animals. Published data suggest that
neonatal and infant consumption of breast milk does not result in substantial
absorption of these maternal antibodies into circulation. A risk to
newborns/infants cannot be excluded. Breast-feeding should be discontinued
during treatment with Arzerra and for 12&nbsp;months following treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>There are no
data on the effects of ofatumumab on human fertility. </span>Effects on male
and female fertility have not been evaluated in animal studies.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>No studies on the effects of </span><span lang=EN-GB>Arzerra<span
style='color:black'> on the ability to drive and use machines have been
performed.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>No detrimental effects
on such activities are predicted from the pharmacology of ofatumumab. The
clinical status of the patient and the ADR profile of ofatumumab should be
borne in mind when considering the patient's ability to perform tasks that
require judgement, motor or cognitive skills (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Summary
of the safety profile</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>The overall safety profile of </span><span
lang=EN-GB>ofatumumab </span><span lang=EN-GB>is based on data from
1,168&nbsp;patients in clinical trials in CLL (see </span><span
style='layout-grid-mode:line'>section&nbsp;5.1</span><span lang=EN-GB>). This
includes 643&nbsp;patients treated with </span><span lang=EN-GB>ofatumumab </span><span
lang=EN-GB>as monotherapy (in </span>patients with relapsed or refractory CLL<span
lang=EN-GB>) and 525&nbsp;patients treated with ofatumumab in combination with
chemotherapy (</span><span lang=EN-GB>chlorambucil or bendamustine or
fludarabine and cyclophosphamide)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Tabulated
list of adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions reported in patients
treated with ofatumumab as monotherapy and with ofatumumab in combination with
chemotherapy, are listed below by MedDRA body system organ class and by
frequency, using the following convention: very common (&#8805;1/10); common
(&#8805;1/100 to &lt;1/10); uncommon (&#8805;1/1,000 to &lt;1/100); rare
(&#8805;1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot
be estimated from available data). Within each frequency grouping, adverse
reactions are ranked in order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>MedDRA
  System Organ Class</span></u></p>
  </td>
  <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Very
  common</span></u></p>
  </td>
  <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Common</span></u></p>
  </td>
  <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Uncommon</span></u></p>
  </td>
  <td valign=top style='border:solid windowtext 1.0pt;border-left:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infections
  and Infestations</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Lower
  respiratory tract infection (including pneumonia), upper respiratory tract
  infection </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Sepsis (including neutropenic sepsis and septic shock)
  herpes viral infection, urinary tract infection</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hepatitis
  B infection a</span><span lang=EN-GB>nd reactivation, progressive multifocal
  leukoencephalopathy</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Neutropenia, anaemia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Febrile neutropenia,
  thrombocytopenia, leukopenia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Agranulocytosis,
  coagulopathy, red cell aplasia, lymphopenia</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Hypersensitivity*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anaphylactic reactions (including
  anaphylactic shock)*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Headache*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span class=CSIchar><span lang=EN-GB style='border:none'>&nbsp;</span></span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Tumour lysis syndrome</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Tachycardia*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Bradycardia*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span class=CSIchar><span lang=EN-GB style='border:none'>&nbsp;</span></span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hypotension*, hypertension*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dyspnoea*, cough*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Bronchospasm*, chest
  discomfort*, oropharyngeal pain*, nasal congestion*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pulmonary oedema*, hypoxia*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span class=CSIchar><span lang=EN-GB style='border:none'>&nbsp;</span></span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nausea*, diarrhoea*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Small intestinal obstruction</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rash*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Urticaria*, pruritus*, flushing*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Back pain*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>General
  disorders and administration site conditions</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Pyrexia*, fatigue*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Cytokine release syndrome*, chills (including rigors)*,
  hyperhidrosis*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td valign=top style='border:solid windowtext 1.0pt;border-top:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Injury,
  poisoning and procedural complications</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Infusion-related
  reaction*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td colspan=5 valign=top style='border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>*These
  events are likely attributable to ofatumumab in the setting of an infusion-related
  reaction and typically occur after the start of infusion and within
  24&nbsp;hours after the completion of the infusion (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Description
of selected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Infusion-related
reactions</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Of the 1,168&nbsp;patients receiving
ofatumumab in clinical trials for CLL, </span>the most frequently observed ADRs
were infusion-related reactions which occurred in 711&nbsp;patients (61%) at
any time during treatment. The majority of infusion-related reactions were
Grade&nbsp;1 or Grade&nbsp;2 in severity. Seven percent of patients had
&#8805;Grade&nbsp;3 infusion-related reactions at any time during treatment.
Two percent of the infusion-related reactions led to discontinuation of
treatment. There were no fatal infusion-related reactions<span lang=EN-GB> (see
section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Infections</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Of the 1,168&nbsp;patients receiving
ofatumumab in clinical trials for CLL, 682&nbsp;patients (58%) experienced an
infection. These included bacterial, viral and fungal infections. 268 (23%) of
the 1,168&nbsp;patients experienced &#8805;Grade&nbsp;3 infections. 65 (6%) of
the 1,168&nbsp;patients experienced a fatal infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Neutropenia</span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Of the 1,168&nbsp;patients receiving
ofatumumab in clinical trials, 420&nbsp;patients (36%) experienced an adverse
event associated with a decreased neutrophil count; 129 (11%) experienced a
serious adverse event associated with a decreased neutrophil count.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the pivotal study for untreated CLL
(OMB110911; ofatumumab plus chlorambucil 217&nbsp;patients, chlorambucil alone
227&nbsp;patients), prolonged neutropenia (defined as Grade&nbsp;3 or 4
neutropenia not resolved between 24 and 42&nbsp;days after last dose of study treatment)
was reported in 41&nbsp;patients (9%) (23&nbsp;patients [11%] treated with </span><span
lang=EN-GB>ofatumumab</span><span lang=EN-GB> and </span>chlorambucil<span
lang=EN-GB>, 18&nbsp;patients [8%] treated with </span>chlorambucil alone<span
lang=EN-GB>). Nine patients (4%) treated with </span><span lang=EN-GB>ofatumumab</span><span
lang=EN-GB> and </span>chlorambucil,<span lang=EN-GB> and three patients
treated with </span>chlorambucil alone<span lang=EN-GB> had late-onset
neutropenia (defined as Grade&nbsp;3 or 4 neutropenia starting at least
42&nbsp;days after the last treatment). </span><span lang=EN-GB>In the pivotal
study (OMB110913, ofatumumab plus fludarabine and cyclophosphamide
181&nbsp;patients; fludarabine and cyclophosphamide 178&nbsp;patients) in
relapsed CLL patients, prolonged neutropenia was reported in 38 (11%) patients
(18&nbsp;patients [10%] treated with ofatumumab in combination with fludarabine
and cyclophosphamide compared to 20&nbsp;patients [11%] in the fludarabine and
cyclophosphamide arm). Thirteen (7%) patients treated with ofatumumab in
combination with fludarabine and cyclophosphamide, and 5 (3%) patients treated
with fludarabine and cyclophosphamide had late-onset neutropenia.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Cardiovascular</span></u></i></p>

<p class=MsoNormal>The effect of multiple doses of Arzerra on the QTc interval
was evaluated in a pooled analysis of three open-label studies in patients with
CLL (N=85). <span style='border:none windowtext 1.0pt;padding:0in'>Increases
above 5&nbsp;msec were observed in the median/mean QT/QTc intervals in the
pooled analysis.<span style='color:black'> </span></span>No large changes in
the mean QTc interval (i.e. &gt;20&nbsp;milliseconds) were detected. None of
the patients had an increase of QTc to &gt;500&nbsp;msec. A concentration
dependent increase in QTc was not detected.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='color:black;background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:#D9D9D9'>Appendix V</span></a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No case of overdose has been reported.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmacotherapeutic
group: antineoplasic agents, monoclonal antibodies, ATC code: L01XC10</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Mechanism of action</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Ofatumumab is a human monoclonal antibody (IgG1) that binds
specifically to a distinct epitope encompassing both the small and large
extracellular loops of the CD20 molecule</span><span lang=EN-GB>. The CD20
molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the
pre-B to mature B lymphocyte stage and on B-cell tumours. The B-cell tumours
include CLL (generally associated with lower levels of CD20 expression) and
non-Hodgkin's lymphomas (where &gt;90% of tumours have high levels of CD20
expression). The CD20 molecule is not shed from the cell surface and is not
internalised following antibody binding.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The binding of ofatumumab to the
membrane-proximal epitope of the CD20 molecule induces recruitment and
activation of the complement pathway at the cell surface, leading to
complement-dependent cytotoxicity and resultant lysis of tumour cells.
Ofatumumab has been shown to induce appreciable lysis of cells with high
expression levels of complement defence molecules. Ofatumumab has also been
shown to induce cell lysis in both high and low CD20 expressing cells and in
rituximab-resistant cells. In addition, the binding of ofatumumab allows the
recruitment of natural killer cells allowing the induction of cell death
through antibody-dependent cell-mediated cytotoxicity.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Pharmacodynamic effects</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Peripheral B-cell counts decreased after the first
ofatumumab infusion in patients with haematological malignancies. <span
lang=EN-GB>In all patients with CLL, ofatumumab induces rapid and profound
B-cell depletion, whether given as a single agent or in combination.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>When ofatumumab was administered as single
agent i</span>n patients with refractory CLL, the median decrease in B-cell
counts was 22% after the first infusion and 92% at the eighth weekly infusion. <span
lang=EN-GB style='color:black'>Peripheral B-cell counts remained low throughout
the remainder of therapy in most patients</span><span lang=EN-GB
style='color:black'> and remained below baseline up to 15&nbsp;months after the
last dose in patients who responded</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>When ofatumumab was administered in
combination with chlorambucil in patients with previously untreated CLL, the
median decreases in B-cell counts after the first cycle and prior to the sixth
monthly cycle were 94% and &gt;99%. At 6&nbsp;months after the last dose, the
median reductions in B-cell counts were &gt;99%</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>When ofatumumab was administered in
combination with fludarabine and cyclophosphamide in patients with relapsed
CLL, </span><span lang=EN-GB>the median decreace from baseline was 60% after
the first infusion and complete depletion (100%) was reached after 4&nbsp;cycles</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span style='layout-grid-mode:
line'>Immunogenicity</span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>There is a potential for immunogenicity </span><span
lang=EN-GB>with therapeutic proteins such as ofatumumab.</span> Serum samples
from more than 1,000&nbsp;patients across the CLL clinical programme were
tested for anti&#8209;ofatumumab antibodies during and after treatment periods
ranging from 8&nbsp;weeks to 2&nbsp;years. <span lang=EN-GB>Formation of anti&#8209;ofatumumab
antibodies was observed for less than 0.5% of patients with CLL after treatment
with </span><span lang=EN-GB>ofatumumab</span><span lang=EN-GB
style='color:black'>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Clinical </span></u><u><span lang=EN-GB style='layout-grid-mode:line'>efficacy
and safety</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><s><span style='text-decoration:
 none'>&nbsp;</span></s></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Previously untreated
CLL</u></i></p>

<p class=MsoNormal>Study OMB110911 (randomised,<span lang=EN-GB> open&#8209;label,
parallel-arm, multicentre)</span><span lang=EN-GB> </span>evaluated the
efficacy of <span lang=EN-GB>Arzerra </span>in combination with chlorambucil
compared with chlorambucil alone in 447&nbsp;patients with previously untreated
CLL<span lang=EN-GB> considered inappropriate for fludarabine-based treatment </span><span
lang=EN-GB>(e.g. due to advanced age or presence of co-morbidities), with
active disease and indicated for treatment</span>. <span lang=EN-GB>Patients
received either Arzerra as monthly intravenous infusions (cycle&nbsp;1:
300&nbsp;mg on day&nbsp;1 and 1000&nbsp;mg on day&nbsp;8; subsequent cycles:
1000&nbsp;mg on day&nbsp;1 every </span><span lang=EN-GB>28&nbsp;days</span><span
lang=EN-GB>) in combination with chlorambucil (</span><span lang=EN-GB>10&nbsp;mg/m<sup>2</sup></span><span
lang=EN-GB style='font-size:8.0pt'> </span><span lang=EN-GB>orally on
days&nbsp;1&#8209;7 every 28&nbsp;days) or chlorambucil alone (10&nbsp;mg/</span><span
lang=EN-GB>m<sup>2</sup></span><span lang=EN-GB style='font-size:8.0pt'> </span><span
lang=EN-GB>orally on days&nbsp;1&#8209;7 every 28&nbsp;days).</span> Patients
received treatment for a minimum of 3&nbsp;months until best response or up to
a maximum of 12&nbsp;cycles. <span lang=EN-GB>The median age was 69&nbsp;years
(range: 35 to 92&nbsp;years), 27% patients were &#8805;75&nbsp;years of age,
63% were male and 89% were white. Median Cumulative Illness Rating Score for
Geriatrics (CIRS-G) was 9 </span>and 31% of patients had a CIRS-G &gt;10.
Median creatinine clearance (CrCl), assessed with the use of the Cockroft-Gault
formula, was 70&nbsp;ml/min and 48% of patients had a CrCl of
&lt;70&nbsp;ml/min. Patients with an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2 were enrolled into the study and 91% had an ECOG
performance status of 0 or 1.<span style='font-size:10.0pt'> </span><span
lang=EN-GB>Approximately 60% of patients received 3&#8209;6&nbsp;cycles of
Arzerra and 32% received 7&#8209;12&nbsp;cycles. </span>The <span lang=EN-GB
style='border:none windowtext 1.0pt;padding:0in'>median number of cycles
completed in patients was 6 (total Arzerra dose of 6300&nbsp;mg).</span></p>

<p class=MsoNormal><a name=IDX></a><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint was median </span><span
lang=EN-GB>progression-free survival (PFS) as assessed by a blinded Independent
Review Committee (IRC) using the International Workshop for Chronic Lymphocytic
Leukaemia (IWCLL) updated National Cancer Institute-sponsored Working Group
(NCI-WG) guidelines (2008).</span><span lang=EN-GB style='font-size:9.0pt'> </span><span
lang=EN-GB>The </span><span lang=EN-GB>overall response rate (ORR) including
complete response (CR) </span><span lang=EN-GB>was also assessed by an </span>IRC<span
lang=EN-GB> using the 2008 IWCLL guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra in combination with chlorambucil
showed a statistically significant (71%) improvement in median PFS compared
with chlorambucil alone (HR: 0.57; 95% CI: 0.45, 0.72) (see Table&nbsp;1 and
Figure&nbsp;1). PFS benefit with the addition of Arzerra was observed in all
patients, including those with poor-risk biological features (such as 17p or
11q deletion, unmutated IGHV, </span><span lang=EN-GB>&#946;2M
&gt;3500&nbsp;&#956;g/l, and ZAP-70 expression)</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Table&nbsp;1       Summary
of PFS with Arzerra in combination with chlorambucil compared with chlorambucil
in previously untreated CLL</span></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:22.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span class=tabletextNS1><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>IRC-assessed
  primary and subgroup analyses of PFS, months</span></b></span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>Chlorambucil</b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(N=226)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:22.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>Arzerra and chlorambucil</b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>(N=221)</b></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Median,
  all patients</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.1</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>22.4</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>95%
  CI</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(10.6,
  13.8)</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(19.0,
  25.2)</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Hazard
  ratio</span></p>
  <p class=tabletextNS style='margin-left:9.0pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>P value</span></p>
  </td>
  <td width=340 colspan=2 valign=top style='width:255.15pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0.57
  (0.45, 0.72)</span></p>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>p&lt;0.001</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Age
  &#8805;75&nbsp;years (n=119)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>12.2</span></p>
  </td>
  <td width=151 style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>23.8</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Co-morbidity&nbsp;0 or 1 (n=126)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>10.9</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>23.0</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Co-morbidity&nbsp;2 or more
  (n=321)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.3</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>21.9</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>ECOG&nbsp;0, 1 (n=411)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.3</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>23.0</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>ECOG&nbsp;2 (n=35)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>7.9</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>20.9</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>CIRS-G &#8804;10 (n=310)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.1</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>21.7</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>CIRS-G </span><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&gt;</span><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>10 (n=137)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>12.2</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>23.2</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>CrCl &lt;70&nbsp;ml/min (n=214)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>10.9</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>23.1</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 style='width:182.6pt;border:solid windowtext 1.0pt;border-bottom:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>CrCl &#8805;70&nbsp;ml/min
  (n=227)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>14.5</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>22.1</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>17p or 11q
  deletion (n=90)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>7.9</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.6</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>IGHV mutated
  (&#8804;98%) (n=177)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>12.2</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>30.5</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>IGHV unmutated
  (&gt;98%) (n=227)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>11.7
  </span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>17.3</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&#946;2M
  &#8804;3500&nbsp;&#956;g/l (n=109)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.8</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>25.5</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&#946;2M
  &gt;3500&nbsp;&#956;g/l (n=322)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>11.6</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>19.6</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>ZAP-70 positive
  (n=161)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>9.7</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>17.7</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>ZAP-70
  intermediate (n=160)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.6</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>25.3</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>ZAP-70 negative
  (n=100)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.8</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>25.6</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>IGHV mutated
  &amp; ZAP-70 negative (n=60)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>10.5</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>NR</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>IGHV mutated
  &amp; ZAP-70 positive (n=35)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>7.9</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>27.2</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>IGHV unmutated
  &amp; ZAP-70 negative (n=27)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>16.7</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>16.2</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=243 valign=top style='width:182.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>IGHV unmutated
  &amp; ZAP-70 positive (n=122)</span></p>
  </td>
  <td width=189 style='width:141.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>11.2</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>16.2</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=584 colspan=3 valign=top style='width:437.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=MsoNormal style='page-break-after:avoid;background:white'><span
  lang=EN-GB style='color:black'>Abbreviations: &#946;2M = beta-2-microglobulin,
  CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for
  Geriatrics, CLL = c</span><span style='color:black'>hronic lymphocytic leukaemia,
  CrCl = creatinine clearance, ECOG = Eastern Cooperative Oncology Group, </span><span
  lang=EN-GB style='color:black'>IGHV = Immunoglobulin Heavy Chain Variable
  Region, IRC = Independent Review Committee, N = number, NR = not reached, PFS
  = progression-free survival, ZAP-70 = zeta-chain-associated protein kinase
  70.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Limited data are available in the heterogeneous non-white
population and in patients with an ECOG performance status of PS&nbsp;=&nbsp;2.</p>

<p class=MsoCaption style='line-height:normal;page-break-after:auto'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=MsoCaption style='line-height:normal'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Figure&nbsp;1      Kaplan-Meier estimates
of IRC-assessed PFS in previously untreated CLL</span></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoCaption style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt;font-family:"Times New Roman",serif'><img border=0
width=590 height=341 id="Picture 5"
src="Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image002.png"
alt="PFS_IRC_4 (2)"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='margin-left:56.7pt;text-indent:-56.7pt;line-height:
normal'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>Table&nbsp;2       Summary
of secondary outcomes of Arzerra in combination with chlorambucil compared with
chlorambucil in previously untreated CLL</span></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
class=tabletextNS1><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:22.9pt'>
  <td width=272 valign=top style='width:203.85pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span class=tabletextNS1><b><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>IRC-assessed
  secondary outcome</span></b></span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:22.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>Chlorambucil</b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>&nbsp;</b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(N=226)</span></b></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 0in 0in 0in;height:22.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>Arzerra and chlorambucil</b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>(N=221)</b></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>ORR (%)</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;border:none;padding:0in 5.4pt 0in 5.4pt;
  height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>69</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>82</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>95%
  CI</span></p>
  </td>
  <td width=161 valign=top style='width:120.5pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(62.1,
  74.6)</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>(76.7,
  87.1)</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>P value</span></p>
  </td>
  <td width=312 colspan=2 valign=top style='width:233.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>p&lt;0.001</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 style='width:203.85pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>CR (%)</span></p>
  </td>
  <td width=161 style='width:120.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>1</span></p>
  </td>
  <td width=151 style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>12</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CR
  with MRD negativity (% of CR)</span></p>
  </td>
  <td width=161 style='width:120.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>0</span></p>
  </td>
  <td width=151 style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>37</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Median duration
  of response</span><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>,
  all patients, months</span></p>
  </td>
  <td width=161 style='width:120.5pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>13.2</span></p>
  </td>
  <td width=151 style='width:113.4pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>22.1</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>95%
  CI</span></p>
  </td>
  <td width=161 style='width:120.5pt;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>(10.8,
  16.4)</span></p>
  </td>
  <td width=151 style='width:113.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>(19.1,
  24.6)</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=272 valign=top style='width:203.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='margin-left:14.2pt;page-break-after:avoid'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>P value</span></p>
  </td>
  <td width=312 colspan=2 valign=top style='width:233.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>p&lt;0.001</span></p>
  </td>
 </tr>
 <tr style='height:13.9pt'>
  <td width=584 colspan=3 valign=top style='width:437.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=tabletextNS style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Abbreviations:
  CI = confidence interval, CLL = c</span><span style='font-size:11.0pt;
  font-family:"Times New Roman",serif'>hronic lymphocytic leukaemia, </span><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>CR =
  complete response, IRC = Independent Review Committee, MRD = minimal residue
  disease, N = number, ORR = overall response rate</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Study OMB115991 evaluated the efficacy of Arzerra in
combination with bendamustine <span lang=EN-GB>in 44&nbsp;patients </span>with
previously untreated CLL <span lang=EN-GB>considered inappropriate for
fludarabine-based treatment</span>. <span lang=EN-GB>Patients received Arzerra
as monthly intravenous infusions (cycle&nbsp;1 300&nbsp;mg on day&nbsp;1 and
1000&nbsp;mg on day&nbsp;8; subsequent cycles: 1000&nbsp;mg on day&nbsp;1 every
28&nbsp;days) in combination with intravenous bendamustine 90&nbsp;mg/m</span><sup><span
lang=EN-GB style='font-size:8.0pt'>2</span></sup><span lang=EN-GB
style='font-size:8.0pt'> </span><span lang=EN-GB>on days&nbsp;1 and 2 every
28&nbsp;days. </span>Patients received treatment for a maximum of 6&nbsp;cycles.
The <span lang=EN-GB style='border:none windowtext 1.0pt;padding:0in'>median
number of cycles completed in patients was 6 (total Arzerra dose of
6300&nbsp;mg).</span></p>

<p class=MsoNormal><span lang=EN-GB style='border:none windowtext 1.0pt;
padding:0in'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint was ORR assessed by
the investigator </span>according to the 2008 <span lang=EN-GB>IWCLL </span>guidelines<span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p><span style='font-size:11.0pt'>The results of this study demonstrated that
Arzerra in combination with bendamustine is an effective therapy providing an
ORR of 95% </span><span lang=EN-GB style='font-size:11.0pt'>(95% CI: 85, 99) </span><span
style='font-size:11.0pt'>and a CR of 43%. More than half of the patients (56%) </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>with CR were MRD negative
following the completion of study treatment.</span></p>

<p><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>No data comparing Arzerra in combination
with bendamustine or with </span><span lang=EN-GB>chlorambucil versus a</span><span
lang=EN-GB> rituximab based regimen such as rituximab with chlorambucil is
available. Thus, the benefit of such a new combination over a rituximab based
regimen is unknown.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><u><span style='font-size:11.0pt'>Relapsed CLL</span></u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Study OMB110913
(randomised, open-label, parallel-arm, multicentre trial) evaluated the
efficacy of ofatumumab in combination with fludarabine and cyclophosphamide
compared with fludarabine and cyclophosphamide in 365&nbsp;patients with
relapsed CLL (</span>defined as a patient who has received at least one prior
CLL therapy and previously achieved a complete or partial remission/response,
but after a period of six or more months demonstrated evidence of disease
progression)<span lang=EN-GB>. Baseline disease characteristics and prognostic
markers were balanced between treatment arms and representative of a relapsed
CLL population. Patient median age was 61&nbsp;years (range: 32 to
90&nbsp;years, 7% were 75&nbsp;years of age or older), 60% were male and 16%,
55% and 28% of patients were Binet stage A, B and C, respectively. The majority
of patients (81%) received 1&#8209;2&nbsp;prior lines of treatments (of whom
approximately 50% received 1&nbsp;prior treatment) and 21% of patients had
received prior rituximab. The median CIRS score was 7 (range:&nbsp;4 to 17),
36% of patients had CrCL </span><span style='font-family:CourierNewPSMT'>&lt;70</span>&nbsp;<span
style='font-family:CourierNewPSMT'>ml/min,</span><span lang=EN-GB> 93% of
patients had ECOG 0 or 1. </span>Limited data are available in the
heterogeneous non-white population and in patients with an ECOG performance
status of 2.</p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>Patients received ofatumumab as intravenous
infusions (cycle&nbsp;1: 300&nbsp;mg on day&nbsp;1 and 1000&nbsp;mg on
day&nbsp;8;</span><span style='font-size:11.0pt'> subsequent cycles:
1000&nbsp;mg on day&nbsp;1 every 28&nbsp;days</span><span lang=EN-GB
style='font-size:11.0pt'>). Approximately 90% of patients received 3&#8209;6&nbsp;cycles
of ofatumumab and 66% completed 6&nbsp;cycles.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The primary endpoint of progression-free
survival (PFS), as assessed by a blinded independent review committee (IRC)
using the updated National Cancer Institute-sponsored Working Group (NCI-WG)
guidelines (2008), was prolonged in the ofatumumab plus
fludarabine-cyclophosphamide (OFA+FC) arm compared to the
fludarabine-cyclophosphamide (FC) arm (28.9&nbsp;months versus 18.8&nbsp;months;
HR: 0.67; 95% CI: 0.51&#8209;0.88, p=0.0032) resulting in a 10-month
improvement in median PFS (see Figure&nbsp;2). PFS based on local
(investigator) assessment was consistent with the primary endpoint and resulted
in a ~11-month improvement in median PFS (OFA+FC 27.2&nbsp;months versus
16.8&nbsp;months for FC; HR=0.66 (95% CI: 0.51, 0.85, p=0.0009).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading7 align=left style='text-align:left;line-height:normal'><b><span
style='font-style:normal'>Figure&nbsp;2      Kaplan-Meier estimates of PFS in
relapsed CLL</span></b></p>

<p class=MsoHeading7 align=left style='text-align:left;line-height:normal'><span
style='position:absolute;z-index:-1895825920;margin-left:-20px;margin-top:16px;
width:605px;height:327px'><img width=605 height=327
src="Arzerra%20II-50%20&amp;%20II-51%20-%20PI%20-%20EN%20-%20clea_files/image003.jpg"></span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>The overall response rate (ORR) was also assessed by
an IRC using the 2008 NCI-WG guidelines. The ORR was higher for OFA+FC versus
FC (84% versus 68%, p=0.0003). Median time to next therapy was longer for the
OFA+FC arm versus FC (48.1&nbsp;months versus 40.1&nbsp;months; HR: 0.73; 95%
CI: 0.51&#8209;1.05). Median time to progression was longer for the OFA+FC arm
versus FC (42.1&nbsp;months versus 26.8&nbsp;months; HR: 0.63; 95% CI: 0.45&#8209;0.87).</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>With a median
follow-up of approximately 34&nbsp;months, 67&nbsp;deaths (37%) in the OFA+FC
arm and 69&nbsp;deaths (38%) in the FC arm were reported. The overall survival
results showed a HR=0.78 (56.4&nbsp;months versus 45.8&nbsp;months for the
OFA+FC arm versus FC arm; 95% CI: 0.56&#8209;1.09; p=0.1410).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Refractory CLL</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra was administered as monotherapy to
223&nbsp;patients with refractory CLL (study Hx-CD20-406). Patient median age
was 64&nbsp;years (range: 41 to 87&nbsp;years), and the majority were male
(73%) and white (96%). Patients received a median of 5&nbsp;prior therapies,
including rituximab (57%). Of these 223&nbsp;patients, 95&nbsp;patients were
refractory to fludarabine and alemtuzumab therapy (defined as </span><span
lang=EN-GB>failure to achieve at least a partial response with fludarabine or
alemtuzumab treatment or disease progression within 6&nbsp;months of the last
dose of fludarabine or alemtuzumab). </span>Baseline cytogenetic (FISH) data
were available for 209&nbsp;patients. 36&nbsp;patients had a normal karyotype
and chromosomal aberrations were detected in 174&nbsp;patients; there were
47&nbsp;patients with 17p deletion, 73&nbsp;patients with 11q deletion,
23&nbsp;patients with trisomy 12q, and 31&nbsp;patients with 13q deletion as
the sole aberration.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>The ORR was 49% in patients refractory to
fludarabine and alemtuzumab (see Table&nbsp;3 for a summary of the efficacy
data from the study). </span><span lang=EN-GB>Patients who had prior rituximab
therapy, either as monotherapy or in combination with other medicinal products,
responded to treatment with Arzerra at a similar rate to those who had not had
prior rituximab therapy.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table&nbsp;3       Summary
of response to Arzerra in patients with refractory CLL</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="57%" style='width:57.06%;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(Primary) endpoint<sup>1</sup></span></p>
  </td>
  <td width="42%" valign=bottom style='width:42.94%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Patients refractory to fludarabine and alemtuzumab</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>n=95</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Overall
  response rate</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>Responders, n (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>47 (49)</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>95.3% CI (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>39, 60</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Response
  rate in patients with prior rituximab therapy</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>Responders, n (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25/56 (45)</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31, 59</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Response
  rate in patients with chromosomal abnormality</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:7.1pt;page-break-after:avoid'><span
  lang=EN-GB>17p deletion</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>Responders, n (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>10/27 (37)</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>19, 58</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:7.1pt;page-break-after:avoid'><span
  lang=EN-GB>11q deletion</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>Responders, n (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>15/32 (47)</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI (%)</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>29, 65</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median
  overall survival</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>Months</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>13.9</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.9, 18.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Progression-free
  survival</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>Months</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>4.6</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.9, 6.3</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median
  duration of response</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.1pt;page-break-after:avoid'><span
  lang=EN-GB>Months</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5.5</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>3.7, 7.2</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Median
  time to next CLL therapy</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>Months</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>8.5</span></p>
  </td>
 </tr>
 <tr>
  <td width="57%" valign=top style='width:57.06%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-indent:24.0pt;page-break-after:avoid'><span
  lang=EN-GB>95% CI</span></p>
  </td>
  <td width="42%" valign=top style='width:42.94%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7.2, 9.9</span></p>
  </td>
 </tr>
 <tr style='height:13.7pt'>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'><sup><span lang=EN-GB>1 </span></sup><span
  lang=EN-GB>The overall response was assessed by an </span>Independent
  Response Committee<span lang=EN-GB> using the 1996 NCI-WG guidelines for CLL.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Improvements
also were demonstrated in components of the NCI-WG response criteria. These included
improvements associated with constitutional symptoms, lymphadenopathy,
organomegaly, or cytopenias (see Table&nbsp;4).</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-56.7pt;page-break-after:
avoid'><b><span lang=EN-GB>Table&nbsp;4       Summary of clinical improvement
with a minimum duration of 2&nbsp;months in refractory patients with
abnormalities at baseline</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="47%" rowspan=2 valign=bottom style='width:47.72%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Efficacy
  endpoint or haematological parameter<sup>a</sup></span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Patients with benefit/patients with abnormality at
  baseline (%)</span></p>
  </td>
 </tr>
 <tr>
  <td width="52%" valign=bottom style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Patients refractory to fludarabine and alemtuzumab</span></p>
  </td>
 </tr>
 <tr style='height:14.2pt'>
  <td width="47%" valign=top style='width:47.72%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Lymphocyte
  count</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.2pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:12.3pt'>
  <td width="47%" valign=top style='width:47.72%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB>&#8805;50% decrease</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.3pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>49/71 (69)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB>Normalisation (&#8804;4x10<sup>9</sup>/l)</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>36/71 (51)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Complete
  resolution of constitutional symptoms<sup>b</sup></span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21/47 (45) </span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Lymphadenopathy<sup>c</sup></span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'>³</span><span lang=EN-GB>50%
  improvement</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>51/88 (58)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB>Complete resolution</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>17/88 (19)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Splenomegaly</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'>³</span><span lang=EN-GB>50%
  improvement</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>27/47 (57)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB>Complete resolution </span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>23/47 (49)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Hepatomegaly</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB style='font-family:Symbol'>³</span><span lang=EN-GB>50%
  improvement</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>14/24 (58)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:27.0pt;text-indent:-3.0pt;page-break-after:
  avoid'><span lang=EN-GB>Complete resolution </span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>11/24 (46)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Haemoglobin
  &lt;11&nbsp;g/dl at baseline to &gt;11&nbsp;g/dl post baseline</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12/49 (24)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Platelet
  counts &#8804;100x10</span><sup><span lang=EN-GB>9</span></sup><span
  lang=EN-GB>/l at baseline to &gt;50% increase or &gt;100x10</span><sup><span
  lang=EN-GB>9</span></sup><span lang=EN-GB>/l post baseline</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>19/50 (38)</span></p>
  </td>
 </tr>
 <tr>
  <td width="47%" valign=top style='width:47.72%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Neutrophils
  &lt;1x10</span><sup><span lang=EN-GB>9</span></sup><span lang=EN-GB>/l at
  baseline to &gt;1.5x10</span><sup><span lang=EN-GB>9</span></sup><span
  lang=EN-GB>/l</span></p>
  </td>
  <td width="52%" valign=top style='width:52.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1/17 (6)</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><sup><span lang=EN-GB>a</span></sup><span lang=EN-GB>         Excludes
  patients visits from date of first transfusion, treatment with
  erythropoietin, or treatment with growth factors. For patients with missing
  baseline data, latest screening/unscheduled data was carried forward to
  baseline.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><sup><span lang=EN-GB>b</span></sup><span lang=EN-GB>        Complete
  resolution of constitutional symptoms (fever, night sweats, fatigue, weight
  loss) defined as the presence of any symptoms at baseline, followed by no
  symptoms present.</span></p>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><sup><span lang=EN-GB>c</span></sup><span lang=EN-GB>         Lymphadenopathy
  measured by sum of the products of greatest diameters (SPD) as assessed by
  physical examination.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Arzerra was also given to a group of patients (n=112) with
bulky lymphadenopathy (defined as at least one lymph node &gt;5&nbsp;cm) who
were also refractory to fludarabine. The ORR in this group was 43% (95.3% CI:
33, 53). The median progression-free survival was 5.5&nbsp;months (95% CI: 4.6,
6.4) and the median overall survival was 17.4&nbsp;months (95% CI: 15.0, 24.0).
The response rate in patients with prior rituximab therapy was 38% (95% CI: 23,
61). These patients also experienced comparable clinical improvement, in terms
of the efficacy endpoints and haematological parameters detailed above, to
patients refractory to both fludarabine and alemtuzumab.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Additionally a group of patients (n=16) who were
intolerant/ineligible for fludarabine treatment and/or intolerant to
alemtuzumab treatment were treated with Arzerra. The overall response rate in
this group was 63% (95.3% CI: 35, 85).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>An open-label,
two arm, randomised study (OMB114242) was conducted in patients with bulky
fludarabine refractory CLL who had failed at least 2&nbsp;prior therapies
(n=122) comparing Arzerra monotherapy (n=79) to physicians choice (PC) of
therapy (n=43). There was no statistically significant difference in the
primary endpoint of IRC assessed PFS (5.4 vs. 3.6&nbsp;months, HR=0.79,
p=0.27). The PFS in the monotherapy Arzerra arm was comparable to the results
seen with Arzerra monotherapy in study Hx-CD20-406.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>A dose-ranging study (</span>Hx-CD20-402) <span
lang=EN-GB>was conducted in 33&nbsp;patients with relapsed or refractory CLL.
Patient median age was 61&nbsp;years (range: 27 to 82&nbsp;years), the majority
were male (58%), and all were white. </span>Treatment with Arzerra (w<span
lang=EN-GB>hen given as 4&nbsp;once-weekly infusions)</span>, led to a 50%
objective response rate in the highest dose group (1st dose: 500&nbsp;mg; 2nd,
3rd and 4th dose: 2,000&nbsp;mg) and included 12&nbsp;partial remissions and
one nodular partial remission. For the highest dose group, the median time to
progression was 15.6&nbsp;weeks (95% CI: 15,22.6) in the full analysis
population, and 23&nbsp;weeks (CI: 20,31) in responders. The duration of
response was 16&nbsp;weeks (CI: 13, 19) and the time to next CLL
therapy was 52.4&nbsp;weeks (CI: 36.9  non-estimable).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Paediatric population</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal>The European Medicines Agency has waived the obligation to
submit the results of studies with Arzerra in all subsets of the paediatric
population in chronic lymphocytic leukaemia (see section&nbsp;4.2 for
information on paediatric use).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Overall, the pharmacokinetics of ofatumumab
were consistent across the indications, whether given as a single agent or in
combination with fludarabine and cyclophosphamide or chlorambucil. Ofatumumab
had non-linear pharmacokinetics related to its decreasing clearance over time.</span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Absorption</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Arzerra is administered by intravenous infusion; therefore,
absorption is not applicable.</p>

<p class=MsoNormal><u><span style='layout-grid-mode:line'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Distribution</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Ofatumumab has a small volume of distribution, with mean Vss
values ranging from 1.7 to 8.1&nbsp;l across studies, dose levels, and infusion
number.</p>

<p class=MsoNormal><span style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Biotransformation</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Ofatumumab is a protein for which the expected metabolic
pathway is degradation to small peptides and individual amino acids by
ubiquitous proteolytic enzymes. Classical biotransformation studies have not
been performed.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='layout-grid-mode:
line'>Elimination</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Ofatumumab is eliminated in two ways: a target-independent
route like other IgG molecules and a target-mediated route which is related to
binding to B-cells. There was a rapid and sustained depletion of CD20<sup>+</sup>
B-cells after the first ofatumumab infusion, leaving a reduced number of CD20<sup>+</sup>
cells available for the antibody to bind at subsequent infusions. As a result,
ofatumumab clearance values were lower and t<sub>½</sub> values were
significantly larger after later infusions than after the initial infusion;
during repeated weekly infusions, ofatumumab AUC and C<sub>max</sub> values
increased more than the expected accumulation based on first infusion data.</p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>The main pharmacokinetic parameters of ofatumumab as a
single agent or in combination are summarised in Table&nbsp;5.</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<h6 style='line-height:normal'><b><span lang=EN-GB style='font-style:normal'>Table&nbsp;5       Ofatumumab
pharmacokinetic parameters (geometric mean)</span></b></h6>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width="26%" valign=top style='width:26.1%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Population
   (treatment)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.94%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dosing regimen </span></p>
   </td>
   <td width="11%" valign=top style='width:11.8%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cycle<sup>(1)</sup></span></p>
   </td>
   <td width="12%" valign=top style='width:12.06%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>C<sub>max</sub>
   (µg/ml)</span></p>
   </td>
   <td width="14%" valign=top style='width:14.22%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>AUC (µg.h/ml)</span></p>
   </td>
   <td width="10%" valign=top style='width:10.58%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>CL (ml/h)</span></p>
   </td>
   <td width="10%" valign=top style='width:10.28%;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Table style='margin:0in;page-break-after:avoid'><span
   style='font-size:11.0pt;font-family:"Times New Roman",serif'>t<sub>½</sub>
   (days)</span></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width="26%" rowspan=2 style='width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Refractory CLL</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(ofatumumab)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1<sup>st</sup>
  infusion (300&nbsp;mg) </span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cycle&nbsp;1</span></p>
  </td>
  <td width="12%" valign=top style='width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>61.4</span></p>
  </td>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2000&nbsp;mg:
  8&nbsp;weekly infusions followed by 4&nbsp;monthly infusions</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>12<sup>th</sup>
  dose</span></p>
  </td>
  <td width="12%" valign=top style='width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>827</span></p>
  </td>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>166000</span></p>
  </td>
  <td width="10%" valign=top style='width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>12.1</span></p>
  </td>
  <td width="10%" valign=top style='width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>11.5</span></p>
  </td>
 </tr>
 <tr>
  <td width="26%" rowspan=2 style='width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Previously
  untreated patients</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(ofatumumab +
  chlorambucil)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1<sup>st</sup>
  infusion (300&nbsp;mg)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cycle&nbsp;1</span></p>
  </td>
  <td width="12%" valign=top style='width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>51.8</span></p>
  </td>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>2620</span></p>
  </td>
  <td width="10%" valign=top style='width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1000&nbsp;mg
  monthly infusions</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cycle&nbsp;4</span></p>
  </td>
  <td width="12%" valign=top style='width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>285</span></p>
  </td>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>65100</span></p>
  </td>
  <td width="10%" valign=top style='width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>15.4 </span></p>
  </td>
  <td width="10%" valign=top style='width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>18.5</span></p>
  </td>
 </tr>
 <tr>
  <td width="26%" rowspan=2 style='width:26.1%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Relapsed CLL</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(ofatumumab +
  FC)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1<sup>st</sup>
  infusion (300&nbsp;mg)</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cycle&nbsp;1</span></p>
  </td>
  <td width="12%" valign=top style='width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>61.4</span></p>
  </td>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>3560</span></p>
  </td>
  <td width="10%" valign=top style='width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width="14%" valign=top style='width:14.94%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>1000&nbsp;mg on
  the 8<sup>th</sup> day of cycle&nbsp;1 followed by 1000&nbsp;mg monthly infusions</span></p>
  </td>
  <td width="11%" valign=top style='width:11.8%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Cycle&nbsp;4</span></p>
  </td>
  <td width="12%" valign=top style='width:12.06%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>313</span></p>
  </td>
  <td width="14%" valign=top style='width:14.22%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>89100</span></p>
  </td>
  <td width="10%" valign=top style='width:10.58%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>11.2</span></p>
  </td>
  <td width="10%" valign=top style='width:10.28%;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>19.9</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=7 valign=top style='width:100.0%;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>(<sup>1</sup>) Cycle
  for which the pharmacokinetic parameters are presented in this table.</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>C<sub>max</sub>:
  maximum ofatumumab concentration at the end of infusion, AUC: exposure to
  ofatumumab over a dosing period, CL: ofatumumab clearance after multiple
  doses, T<sub>½</sub>: terminal half-life</span></p>
  <p class=Table style='margin:0in;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Numbers rounded
  to three significant digits</span></p>
  </td>
 </tr>
</table>

<p class=Text align=left style='margin-top:0in;text-align:left'><span
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Special populations</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Elderly (&#8805;65&nbsp;years
of age)</u></i></p>

<p class=MsoNormal>Age was not found to be a significant factor for ofatumumab
pharmacokinetics in a cross-study population pharmacokinetic analysis of
patients ranging in age from 21 to 87&nbsp;years of age.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Paediatric population</u></i></p>

<p class=MsoNormal>No pharmacokinetic data are available in paediatric
patients.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Gender</u></i></p>

<p class=MsoNormal>Gender had a modest effect (12%) on ofatumumab central
volume of distribution in a cross-study population analysis, with higher C<sub>max</sub>
and AUC values observed in female patients (48% of the patients in this
analysis were male and 52% were female); these effects are not considered
clinically relevant, and no dose adjustment is recommended.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Renal impairment</u></i></p>

<p class=MsoNormal>Baseline calculated creatinine clearance was not found to be
a significant factor on ofatumumab pharmacokinetics in a cross-study population
analysis in patients with calculated creatinine clearance values ranging from
26 to 287&nbsp;ml/min. No dose adjustment is recommended for mild to moderate
renal impairment (creatinine clearance &gt;30&nbsp;ml/min). There are limited
pharmacokinetic data in patients with severe renal impairment (creatinine
clearance &lt;30&nbsp;ml/min).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>Hepatic impairment</u></i></p>

<p class=MsoNormal>No formal studies were conducted to examine the effect of
hepatic impairment. IgG1 molecules such as ofatumumab are catabolised by
ubiquitous proteolytic enzymes, which are not restricted to hepatic tissue;
therefore, changes in hepatic function are unlikely to have any effect on the
elimination of ofatumumab.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Preclinical data reveal no special hazards
for humans.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous and subcutaneous administration
to monkeys resulted in the expected depletion of peripheral and lymphoid tissue
B-cell counts with no associated toxicological findings. As anticipated, a
reduction in the IgG humoral immune response to keyhole limpet h<span
style='color:black'>a</span>emocyanin was noted, but there were no effects on
delayed-type hypersensitivity responses. In a few animals, increased red cell
destruction occurred, presumably as a result of monkey anti-drug antibodies<span
style='color:green'> </span><span style='color:black'>coating the red cells.</span>
A corresponding increase in reticulocyte counts seen in these monkeys was
indicative of a regenerative response in the bone marrow.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous administration of ofatumumab to
pregnant cynomolgus monkeys at 100&nbsp;mg/kg once weekly from days&nbsp;20 to
50 of gestation did not elicit maternal or foetal toxicity or teratogenicity.
At the end of organogenesis (day&nbsp;48 of gestation), the ofatumumab exposure
(AUC<sub>inf</sub>) corresponded to 0.46 to 3.6&nbsp;times the human exposure
after the eighth infusion of the maximum recommended human dose (MRHD) of 2000&nbsp;mg.
At day&nbsp;100 of gestation, depletion of B-cells relating to the
pharmacological activity of ofatumumab were observed in foetal cord blood and
foetal splenic tissues. Spleen weights decreased by approximately 15% in the low-dose
group and by approximately 30% in the high-dose group, compared with control
values.</span><span lang=EN-GB> </span><span lang=EN-GB>Pre- and post-natal
development studies have not been performed. Post-natal recovery has therefore
not been demonstrated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>As ofatumumab is a monoclonal antibody,
genotoxicity and carcinogenicity studies have not been conducted with
ofatumumab.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Arginine</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Sodium acetate (E262)</span></p>

<p class=MsoNormal><span lang=IT style='color:black'>Sodium chloride</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Polysorbate 80 (E433)</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Edetate disodium (E386)</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Hydrochloric acid (E507)
(for pH-adjustment)</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Water for injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>This medicinal product
must not be mixed with other medicinal products except those mentioned in
section&nbsp;6.6.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Vial</span></u></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Diluted
infusion solution</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Chemical and physical
in-use stability has been demonstrated for 48&nbsp;hours at ambient conditions
(less than 25°C).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>From a microbiological point of view, the
medicinal product should be used immediately. If not used immediately, in-use
storage times and conditions prior to use are the responsibility of the user
and would normally not be longer than 24&nbsp;hours at 2-8&nbsp;ºC, unless
reconstitution/dilution has taken place in controlled and validated aseptic
conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;background:white'><span
class=CSIchar><span lang=EN-GB style='border:none'>&nbsp;</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Store and transport
refrigerated (2</span><span lang=EN-GB style='font-family:Symbol;color:black'>°</span><span
lang=EN-GB style='color:black'>C  8</span><span lang=EN-GB style='font-family:
Symbol;color:black'>°</span><span lang=EN-GB style='color:black'>C).</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Keep the vial in the
outer carton in order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions after dilution of
the medicinal product, see section&nbsp;6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Arzerra 100&nbsp;mg concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Clear Type I glass vial
with a bromobutyl rubber stopper and aluminium over-seal, containing 5&nbsp;ml
of concentrate for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Arzerra is available in
packs of 3&nbsp;vials.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Arzerra 1000&nbsp;mg concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Clear Type I glass vial
with a bromobutyl rubber stopper and aluminium over&#8209;seal, containing
50&nbsp;ml of concentrate for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Arzerra is available in
packs of 1&nbsp;vial.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>6.6     </span></b><b><span lang=EN-GB>Special
precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Dilution</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra </span><span lang=EN-GB>concentrate
for solution for infusion </span><span lang=EN-GB>does not contain a
preservative; therefore dilution should be carried out under aseptic
conditions. The diluted solution for infusion must be used within 24&nbsp;hours
of preparation. Any unused solution remaining after this time should be
discarded.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u>Before
diluting Arzerra</u></i></p>

<p class=MsoNormal style='text-autospace:none'>Check the<i> </i><span
lang=EN-GB>Arzerra concentrate<i> </i>for particulate matter and discolouration
prior to dilution. Ofatumumab should be a colourless to pale yellow solution.
Do not use the Arzerra concentrate if there is discolouration.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not shake
the ofatumumab vial for this inspection.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u>How
to dilute the solution for infusion</u></i></p>

<p class=MsoNormal style='text-autospace:none'>The <span lang=EN-GB>Arzerra</span>
concentrate must be diluted in <span lang=EN-GB>sodium chloride 9&nbsp;mg/ml
(0.9%) solution for injection</span> prior to administration, using aseptic
technique.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Arzerra 100&nbsp;mg concentrate for solution for infusion</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>300&nbsp;mg dose: Use 3&nbsp;vials (15&nbsp;ml total, 5&nbsp;ml per
vial)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw and discard 15&nbsp;ml from a
1000&nbsp;ml bag of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw 5&nbsp;ml of ofatumumab from each of 3</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>vials and inject into the 1000&nbsp;ml
bag;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not shake; mix diluted solution by gentle
inversion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
style='color:black'>Arzerra 1000&nbsp;mg concentrate for solution for infusion</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>1000&nbsp;mg dose: Use 1&nbsp;vial (50&nbsp;ml total, 50&nbsp;ml per
vial)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw and discard 50&nbsp;ml from a
1000&nbsp;ml bag of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw 50&nbsp;ml of ofatumumab from the vial
and inject into the 1000&nbsp;ml bag;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not shake; mix diluted solution by gentle
inversion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>2000&nbsp;mg dose: Use 2&nbsp;vials (100&nbsp;ml total, 50&nbsp;ml
per vial)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw and discard 100&nbsp;ml from a
1000&nbsp;ml bag of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw 50&nbsp;ml of ofatumumab from each of
2&nbsp;vials and inject into the 1000&nbsp;ml bag;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:"Tms Rmn",serif;color:black'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not shake; mix diluted solution by gentle
inversion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u>How
to administer the diluted solution</u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra must
not be administered as an intravenous push or bolus. Administer using an
intravenous infusion pump</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The infusion must be completed within
24&nbsp;hours after preparation. Discard any unused solution after this time.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra must not be mixed with, or
administered as an infusion with other medicinal products or intravenous
solutions. Flush line before and after ofatumumab administration with sodium
chloride 9&nbsp;mg/ml (0.9%) solution for injection to avoid this.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Previously
untreated CLL and relapsed CLL</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the first infusion, administer over
4.5&nbsp;hours </span><span lang=EN-GB>(</span><span lang=EN-GB>see
section&nbsp;4.2</span><i><span lang=EN-GB>)</span></i><span lang=EN-GB>, </span><span
lang=EN-GB>through a peripheral line or indwelling catheter, according to the
schedule below:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>If the first infusion was completed without a severe adverse
reaction, the remaining infusions of 1000&nbsp;mg should be administered over
4&nbsp;hours (see section&nbsp;4.2</span><i><span lang=EN-GB>)</span></i><span
lang=EN-GB>, through a peripheral line or indwelling catheter, </span><span
lang=EN-GB>according to the schedule below.</span><span lang=EN-GB> If any
infusion&#8209;related adverse reactions are observed, infusion should be
interrupted and restarted when the patients condition is stable (see </span><span
lang=EN-GB>section&nbsp;4.2 for further information).</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u><span
lang=EN-GB>Infusion schedule</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width=236 rowspan=2 style='width:176.65pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Time after start of infusion (minutes)</span></p>
  </td>
  <td width=188 style='width:141.15pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion&nbsp;1</span></p>
  </td>
  <td width=195 style='width:146.55pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Subsequent infusions*</span></p>
  </td>
 </tr>
 <tr>
  <td width=188 style='width:141.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
  <td width=195 style='width:146.55pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0&#8209;30</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31&#8209;60</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61&#8209;90</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>91&#8209;120</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>121&#8209;150</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>151&#8209;180</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>300</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>180+</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>*If the
  previous infusion was completed without severe infusion&#8209;related ADRs.
  If any infusion&#8209;related ADRs are observed, infusion should be
  interrupted and restarted when the patients condition is stable (see </span><span
  lang=EN-GB>section&nbsp;4.2 of the SmPC</span><span lang=EN-GB>).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Refractory CLL</u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the first and second infusion,
administer over 6.5&nbsp;hours (see section&nbsp;4.2), through a peripheral
line or indwelling catheter, according to the schedule below:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If the second infusion was completed
without a severe adverse reaction, the remaining infusions (3&#8209;12) should
be administered over 4&nbsp;hours (see section&nbsp;4.2), through a peripheral
line or indwelling catheter, according to the schedule below.</span><span
lang=EN-GB> If any infusion&#8209;related adverse reactions are observed,
infusion should be interrupted and restarted when the patients condition is
stable (see </span><span lang=EN-GB>section&nbsp;4.2 for further information).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Infusion
schedule</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 rowspan=2 style='width:154.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Time after start of infusion (minutes)</span></p>
  </td>
  <td width=180 style='width:134.7pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusions&nbsp;1 and 2</span></p>
  </td>
  <td width=179 style='width:134.6pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusions&nbsp;3* to 12</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 style='width:134.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
  <td width=179 style='width:134.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0&#8209;30</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31&#8209; 60</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61&#8209;90</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>91&#8209;120</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>121+</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=565 colspan=3 valign=top style='width:423.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>*If the
  second infusion is completed without severe infusion&#8209;related ADRs. If
  any infusion&#8209;related ADRs are observed, infusion should be interrupted
  and restarted when the patients condition is stable (see section&nbsp;4.2).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If any adverse reactions are observed,
infusion rates should be reduced (see section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Disposal</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Frimley
Business Park</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Camberley
GU16 7SR</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>United Kingdom</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Arzerra 100&nbsp;mg concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/10/625/001</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>Arzerra 1000&nbsp;mg concentrate for solution for infusion</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>EU/1/10/625/003</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION/RENEWAL
OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Date of
first authorisation: </span><span lang=EN-GB>19 April 2010</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 17 February 2015</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicinal product </span><span lang=EN-GB>is available on
the website of the European Medicines Agency (EMA) </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext;text-decoration:
none'>http://www.ema.europa.eu</span></a></span><span lang=EN-GB>/.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>A.        MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>B.        CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoBlockText><span lang=EN-GB>C.        OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoBlockText><span lang=EN-GB>D.        CONDITIONS OR RESTRICTIONS
WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=X-NONE>A.      MANUFACTURERS OF THE BIOLOGICAL
ACTIVE SUBSTANCE AND MANUFACTURER</span>S<span lang=X-NONE> RESPONSIBLE FOR
BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:70.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturers of
the biological active substance</span></u></p>

<p class=MsoNormal style='margin-right:70.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Lonza Biologics plc</p>

<p class=MsoNormal>228 Bath Road</p>

<p class=MsoNormal>Slough, Berks SL1 4DX</p>

<p class=MsoNormal>United Kingdom</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Lonza Biologics, Inc.</p>

<p class=MsoNormal>101 International Drive</p>

<p class=MsoNormal>Portsmouth, NH 03801-2815</p>

<p class=MsoNormal>United States</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturers
responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Glaxo Operations UK Ltd.</p>

<p class=MsoNormal>Harmire Road</p>

<p class=MsoNormal>Barnard Castle</p>

<p class=MsoNormal>Durham, DL12 8DT</p>

<p class=MsoNormal>United Kingdom</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Novartis Pharmaceuticals UK Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>Frimley Business Park</span></p>

<p class=MsoNormal><span lang=EN-GB>Frimley</span></p>

<p class=MsoNormal><span lang=EN-GB>Camberley, Surrey GU16 7SR</span></p>

<p class=MsoNormal><span lang=EN-GB>United Kingdom</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Novartis Pharma GmbH</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Roonstrasse 25</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>90429 Nuremberg</span></p>

<p class=MsoNormal><span lang=EN-GB>Germany</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The printed package leaflet of the medicinal product must
state the name and address of the manufacturer responsible for the release of
the concerned batch.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=X-NONE>B.      CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (see Annex I: Summary of Product Characteristics,
section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><span class=TitleBChar><span lang=EN-GB>C.      OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING</span></span><b><span lang=EN-GB> AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The requirements for submission of periodic
safety update reports for this medicinal product are set out in the list of
Union reference dates (EURD list) provided for under Article 107c(7) of
Directive 2001/83</span><span lang=EN-GB>/EC</span><span lang=EN-GB> and any
subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><span class=TitleBChar><span lang=EN-GB>D.      CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></span></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The MAH shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the Marketing Authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>An updated
RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.4pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-right:28.3pt;text-align:center'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
 AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=X-NONE>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra </span><span
lang=EN-GB style='color:black'>100&nbsp;mg concentrate for solution for
infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>ofatumumab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One ml contains
20&nbsp;mg ofatumumab.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
100&nbsp;mg ofatumumab in 5&nbsp;ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Also contains: arginine,
sodium acetate (E262), </span><span lang=EN-GB style='color:black'>sodium
chloride</span><span lang=PT style='color:black'>, polysorbate 80 (E433),
edetate disodium (E386), hydrochloric acid (E507), </span><span lang=EN-GB
style='color:black'>water for injections. See leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM
 AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>Concentrate
for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>100&nbsp;mg/5&nbsp;ml</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>3&nbsp;vials</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store and
transport refrigerated.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Do not
freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
 AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>Frimley Business Park</span></p>

<p class=MsoNormal><span lang=EN-GB>Camberley GU16 7SR</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>United Kingdom</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>EU/1/10/625/001</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><span
lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><span
lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><a name="_Hlk258415279"><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE </span></b></a><b><span lang=EN-GB>PAC</span></b><b><span lang=EN-GB>KAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>VIAL
LABEL</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=IT>Arzerra<i> </i></span><span
lang=IT style='color:black'>100&nbsp;mg sterile concentrate</span></p>

<p class=MsoNormal><span lang=IT>ofatumumab</span></p>

<p class=MsoNormal><span lang=IT>IV</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>100&nbsp;mg/5&nbsp;ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra </span><span
lang=EN-GB style='color:black'>1000&nbsp;mg concentrate for solution for
infusion</span></p>

<p class=MsoNormal><span lang=EN-GB>ofatumumab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.       STATEMENT OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>One ml contains
20&nbsp;mg ofatumumab.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Each vial contains
1000&nbsp;mg ofatumumab in 50&nbsp;ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.       LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=PT style='color:black'>Also contains: arginine,
sodium acetate (E262), </span><span lang=EN-GB style='color:black'>sodium chloride</span><span
lang=PT style='color:black'>, polysorbate 80 (E433), edetate disodium (E386),
hydrochloric acid (E507), </span><span lang=EN-GB style='color:black'>water for
injections. See leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL FORM
 AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>Concentrate
for solution for infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>1000&nbsp;mg/50&nbsp;ml</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>1&nbsp;vial</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.       METHOD AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Intravenous use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.       SPECIAL WARNING THAT THE MEDICINAL
PRODUCT MUST BE STORED OUT OF THE <span style='text-transform:uppercase'>sight
and</span> REACH OF CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.       OTHER SPECIAL WARNING(S), IF
NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.       EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL STORAGE
CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Store and
transport refrigerated.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Do not
freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL
PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
 AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Novartis Europharm Limited</span></p>

<p class=MsoNormal><span lang=EN-GB>Frimley Business Park</span></p>

<p class=MsoNormal><span lang=EN-GB>Camberley GU16 7SR</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>United Kingdom</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EU/<span lang=EN-GB>1/10/625/003</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#CCCCCC'>Justification
for not including Braille accepted</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>2D
barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='page-break-after:avoid;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><span
lang=EN-GB>PC:</span></p>

<p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><span
lang=EN-GB>SN:</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>NN:</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>VIAL
LABEL</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=IT>Arzerra<i> </i></span><span
lang=IT style='color:black'>1000&nbsp;mg sterile concentrate</span></p>

<p class=MsoNormal><span lang=IT>ofatumumab</span></p>

<p class=MsoNormal><span lang=IT>IV</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<p class=MsoNormal><span lang=IT>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>1000&nbsp;mg/50&nbsp;ml</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><u><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></u></b>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=X-NONE>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'><a name="OLE_LINK1"><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></a></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>Arzerra </span></b><b><span lang=EN-GB style='color:black'>100&nbsp;mg
concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center;text-autospace:none'><b><span
lang=EN-GB>Arzerra </span></b><b><span lang=EN-GB style='color:black'>1000&nbsp;mg
concentrate for solution for infusion</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>ofatumumab</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you are given this medicine because it contains important information
for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Tms Rmn",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Tms Rmn",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:"Tms Rmn",serif'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or nurse. This includes any possible side effects not listed in this leaflet.
See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>What is in
this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>1.       What Arzerra
is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>2.       What
you need to know before you are given Arzerra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>3.       How Arzerra
is given</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>4.       Possible
side effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>5.       How
to store Arzerra</span></p>

<p class=MsoNormal style='margin-right:-1.45pt'><span lang=EN-GB>6.       </span><span
lang=EN-GB>Contents of the pack and other</span><span lang=EN-GB> information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>1.       What Arzerra is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra</span><span lang=EN-GB> contains ofatumumab</span><span
lang=EN-GB>, which belongs to a group of medicines called monoclonal antibodies.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Arzerra</span></b><b><span lang=EN-GB>
is used to treat chronic lymphocytic leukaemia</span></b><span lang=EN-GB> (CLL).
 CLL is a cancer of the blood which affects </span><span lang=EN-GB>a type of
white blood cell called lymphocytes. The lymphocytes multiply too quickly and
live too long, so there are too many of them circulating in your blood. The
disease can also affect other organs in your body. </span><span lang=EN-GB>The
antibody in Arzerra recognises a substance on the surface of lymphocytes and
causes the lymphocyte to die.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>2.       What you need to know before you are given Arzerra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>You must
not be given Arzerra:</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic (hypersensitive) to
ofatumumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB
style='color:black'>Check with your doctor<b> </b></span><span lang=EN-GB
style='color:black'>if you think this may apply to you.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Talk to your doctor or nurse before you are given Arzerra</span><span
lang=EN-GB style='color:black'>:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have had <b>heart problems,</b></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have <b>lung disease,</b></span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB
style='color:black'>Check with your doctor<b> </b>if you think any of these may
apply to you. You may need extra check-ups while you are being treated with
Arzerra.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;vertical-align:baseline'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-left:0in'><span lang=EN-GB>Your doctor
may test the amount of electrolytes, such as magnesium and potassium, in your
blood<b><span style='color:#1F497D'> </span></b>before and during your
treatment with Arzerra.<b> </b>Your doctor may treat you if any electrolyte
imbalance is detected.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Vaccination
and Arzerra</span></b></p>

<p class=MsoNormal>If you are having any vaccinations tell your doctor, or the
person giving you the vaccine, that you are being treated with Arzerra. <span
lang=EN-GB>Your response to the vaccine may be weakened</span> and you may not
be fully protected.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Hepatitis
B</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You should be tested for hepatitis B (a
liver disease) before starting Arzerra treatment. If you have had hepatitis B,
Arzerra could cause it to become active again. Your doctor may treat you with a
suitable anti-viral medicine to help prevent this.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have or have had hepatitis B, </span><span
lang=EN-GB>tell your doctor before you are given Arzerra</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Infusion
reactions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Medicines of this type (monoclonal
antibodies) can cause infusion reactions when they are injected into the body.
You will be given medicines such as anti-histamines, steroids or pain relievers
to help reduce any reaction. See also section&nbsp;4, Possible side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you think you have had such a reaction
before, tell your doctor before you are given </span>Arzerra.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Progressive
multifocal leukoencephalopathy (PML)</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Progressive multifocal leukoencephalopathy
(PML), a serious and life-threatening brain condition, has been reported with
medicines like Arzerra. </span><b><span lang=EN-GB>Tell your doctor immediately</span></b><span
lang=EN-GB> if you have memory loss, trouble thinking, difficulty with walking
or loss of vision. If you had these symptoms prior to treatment with Arzerra, <b>tell
your doctor immediately</b> about any changes in these symptoms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Text align=left style='margin-top:0in;text-align:left;page-break-after:
avoid'><b><span style='font-size:11.0pt'>Bowel obstruction</span></b></p>

<p class=Text align=left style='margin-top:0in;text-align:left'><b><span
style='font-size:11.0pt'>Contact your doctor immediately</span></b><span
style='font-size:11.0pt'> if you experience constipation, a swollen abdomen or
abdominal pain. These could be symptoms of a blockage in the bowel, especially
during the early stages of your treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Children
and adolescents</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>It is not known
whether Arzerra works in children and adolescents. Therefore Arzerra is not
recommended for use in children and adolescents.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Arzerra</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Tell your doctor
or pharmacist if you are using, have recently used or might use any other
medicines. This includes herbal medicines and other medicines you can obtain
without a prescription.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy,
breast-feeding and fertility</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>Arzerra is not usually recommended for use during pregnancy.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Tell your doctor if you are
pregnant or breast-feeding, think you may be pregnant, or are planning to have
a baby. </span><span lang=EN-GB>Your doctor will weigh up the benefit to you
against the risk to your baby of taking Arzerra while you're pregnant.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Use a reliable method of
contraception </span><span lang=EN-GB style='color:black'>to avoid becoming<b> </b>pregnant
while you are being treated with Arzerra, </span>and for 12&nbsp;months after
your last dose of Arzerra. Ask your doctor for advice if you are planning to
become pregnant after this period.</p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you do become pregnant during treatment with
Arzerra, tell your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>It is not known
whether the ingredients in Arzerra pass into human milk. Breast-feeding is not
recommended during treatment with Arzerra and for 12&nbsp;months after the last
dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Arzerra is unlikely to affect your ability to drive or use
machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Arzerra
contains sodium</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Arzerra contains 34.8&nbsp;mg sodium in
each 300&nbsp;mg dose, 116&nbsp;mg sodium in each 1000&nbsp;mg dose and
232&nbsp;mg sodium in each 2000&nbsp;mg dose. You need to take this into
account if you are on a controlled sodium diet.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>3.       How Arzerra is given</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If you have any
questions on the use of Arzerra, ask the doctor or nurse who is giving you the
infusion.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>The usual dose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>The usual dose of Arzerra for the first
infusion is 300&nbsp;mg. This dose will be increased, usually to 1000&nbsp;mg
or 2000&nbsp;mg, for the remaining infusions.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>How it is given</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra is
given into a vein (intravenously) as an infusion (a drip) over several hours.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>If you have
not been previously treated for CLL you will have a maximum of
13&nbsp;infusions.</span></b><span lang=EN-GB> You will be given an initial
infusion followed by a second infusion 7&nbsp;days later. The remaining
infusions will then be given once a month for up to 11&nbsp;months.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>If you have
been previously treated for CLL but the disease returns you will have a maximum
of 7&nbsp;infusions.</span></b><span lang=EN-GB> You will be given an initial
infusion followed by a second infusion 7&nbsp;days later. The remaining
infusions will then be given once a month for up to 6&nbsp;months.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>If you have
been previously treated for CLL </span></b><b><span lang=EN-GB
style='color:black'>you will usually have a course of 12&nbsp;infusions.</span></b><span
lang=EN-GB style='color:black'> You will be given an infusion once a week for
eight weeks. This is followed by a four- to five-week gap. The remaining
infusions will then be given once a month for four months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Medicines
given before each infusion</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Before each infusion of Arzerra, you will
be given <b>pre-medication</b> &#8209; medicines which help to reduce any
infusion reactions. These may include anti-histamines, steroids and pain relievers.
You will be checked closely and if you do have any reactions these will be
treated.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Infusion-related
reactions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Medicines of this type (monoclonal
antibodies) can cause infusion-related reactions, which are occasionally
severe, and can cause death. They are more likely during the first treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Very
common symptoms of an infusion-related reaction</span></b><span lang=EN-GB>
(may affect more than 1 in 10&nbsp;people):</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling sick (nausea)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high temperature</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>skin rash</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-27.8pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breathlessness, cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lack of energy</span></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Common symptoms
of an infusion-related reaction</span></b><span lang=EN-GB> (may affect up to 1
in 10&nbsp;people):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions, sometimes severe where
symptoms include raised and itchy rash (hives), swelling of the face or the
mouth (angioedema) causing difficulty breathing and collapse</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty in breathing, shortness of breath,
chest tightness, cough</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low blood pressure (can cause light-headedness
when you stand up)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>flushing</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>excessive sweating</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shaking or shivering</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rapid heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>headache</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>back pain</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>high blood pressure</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>throat pain or irritation</span><a
name="OLE_LINK2"></a></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blocked nose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Uncommon
symptoms of an infusion-related reaction</span></b><span lang=EN-GB> (may
affect up to 1 in 100&nbsp;people):</span></p>

<p class=MsoCommentText style='margin-left:28.35pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=X-NONE style='font-size:11.0pt'>anaphylactic reaction
including anaphylactic shock, where symptoms include breathlessness or
difficult</span><span style='font-size:11.0pt'>y</span><span lang=X-NONE
style='font-size:11.0pt'> breathing, wheezing or coughing, light-headedness,
dizziness, changes in levels of consciousness, hypotension, with or without
mild generali</span><span style='font-size:11.0pt'>s</span><span lang=X-NONE
style='font-size:11.0pt'>ed itching, skin reddening, swelling</span><span
style='font-size:11.0pt'> of the face and/or throat</span><span lang=X-NONE
style='font-size:11.0pt'>, blue discolouration of the lips, tongue or skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fluid in the lungs (pulmonary oedema) causing
breathlessness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>slow heart beat</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blue discolouration of the lips and extremities
(possible symptoms of hypoxia)</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><b><span lang=EN-GB>Tell your doctor or a nurse immediately if you get
any of these symptoms.</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
possible side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>Very common side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>These may affect more than 1 in 10&nbsp;people:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>frequent infections, fever, chills, sore throat
or mouth ulcers due to infections</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fever, coughing, difficulty breathing, wheezing,
possible symptoms of </span><span lang=EN-GB>infections of the lungs or airways
(respiratory tract) including pneumonia</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sore throat, feeling of pressure or pain in the
cheeks and forehead</span><span lang=EN-GB>, infections of the ear, nose or
throat.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>Very common side effects that may show up in
your blood tests:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low levels of white blood cells (neutropenia)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>low levels of red blood
cells (anaemia).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>Common side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>These may affect up to 1 in 10&nbsp;people:</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>fever or, alternatively, a very
low body temperature, chest pain, shortness of breath or rapid breathing,
shaking, chills, confusion, dizziness, decreased urination and rapid pulse,
(possible symptoms of blood infection)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>difficulty and pain when passing urine,
exaggerated sense of needing to urinate,</span><span lang=EN-GB> urinary tract
infections</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shingles, cold sores </span><span lang=EN-GB>(possible
symptoms of herpes viral infection that can potentially be severe)</span><span
lang=EN-GB>.</span></p>

<p class=Bullet style='margin:0in;margin-bottom:.0001pt;text-indent:0in;
line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>Common side effects that may show up in your
blood tests:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low levels of platelets in the blood (cells that
help blood to clot).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB style='color:black'>Uncommon side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>These may affect up to 1 in 100&nbsp;people:</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>blockage in the gut (intestine), which may feel
like stomach pain.</span></p>

<p class=Bullet style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>If you have persistent
stomach pain, <b>see your doctor as soon as possible.</b></span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>yellow skin and eyes, nausea, loss
of appetite, dark urine (possible symptoms of an infection or reactivation of
hepatitis B virus)</span></p>

<p class=Listlevel1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
style='font-size:11.0pt;font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span style='font-size:11.0pt'>memory loss, trouble with
thinking, and difficulty with walking or loss of vision (possible symptoms of
progressive multifocal leukoencephalopathy)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-family:Symbol;
color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>increase in potassium,
phosphate and uric acid in the blood that can cause kidney problems (tumour
lysis syndrome)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid;
text-autospace:none'><span lang=EN-GB>The symptoms of this condition include:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>producing less urine than normal</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle spasms.</span></p>

<p class=MsoListParagraph style='margin-left:28.35pt'><span lang=EN-GB
style='color:black'>If you notice these symptoms, <b>contact your doctor as
soon as possible</b>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB style='color:black'>Uncommon side effects that may show up in your blood
tests:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>problems with blood clotting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-27.8pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>the bone marrow failing to
produce enough red or white blood cells</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=BodytextAgency style='margin-bottom:0in;line-height:normal'><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'>If you
get any side effects, talk to your doctor or nurse.<span style='color:red'> </span>This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='color:black;background:#D9D9D9'>the
national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif;
background:#D9D9D9'>Appendix V</span></a><span lang=X-NONE style='font-size:
11.0pt;font-family:"Times New Roman",serif'>. By reporting side effects you can
help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.       How to store Arzerra</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Do not use this
medicine after the expiry date shown on the carton and vial label. The expiry
date refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store and transport refrigerated (2&nbsp;C
 8</span><span lang=EN-GB style='font-family:Symbol'>°</span><span lang=EN-GB>C).</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the vial in the outer carton in order
to protect from light.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store the diluted infusion solution between
2</span><span lang=EN-GB style='font-family:Symbol'>°</span><span lang=EN-GB>C
and 8&nbsp;C and use within 24&nbsp;hours. Any unused infusion solution should
be discarded 24&nbsp;hours after preparation.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>6.       Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Arzerra contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is ofatumumab. One ml of
concentrate contains 20&nbsp;mg of ofatumumab.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=PT style='color:black'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are </span><span lang=PT
style='color:black'>arginine, sodium acetate (E262), </span><span lang=EN-GB
style='color:black'>sodium chloride</span><span lang=PT style='color:black'>,
polysorbate 80 (E433), edetate disodium (E386), hydrochloric acid (E507) (for
pH-adjustment), </span><span lang=EN-GB style='color:black'>water for
injections (see Arzerra contains sodium under section&nbsp;2).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>What
Arzerra looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Arzerra is a </span><span
lang=EN-GB>colourless to pale yellow concentrate for solution</span><span
lang=EN-GB style='color:black'> for infusion.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB
style='color:black'>Arzerra 100&nbsp;mg</span></b><span lang=EN-GB
style='color:black'> is available in a pack containing 3&nbsp;vials</span><span
lang=EN-GB>. Each glass vial is closed with a rubber stopper and aluminium
over-seal</span><span lang=EN-GB style='color:black'>, and contains 5&nbsp;ml
of concentrate (100</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB
style='color:black'>mg of ofatumumab).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB
style='color:black'>Arzerra 1000&nbsp;mg</span></b><span lang=EN-GB
style='color:black'> is available in a pack containing 1&nbsp;vial</span><span
lang=EN-GB>. Each glass vial is closed with a rubber stopper and aluminium
over-seal</span><span lang=EN-GB style='color:black'>, and contains 50&nbsp;ml
of concentrate (1000</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB
style='color:black'>mg of ofatumumab).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Novartis
Europharm Limited</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Frimley
Business Park</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Camberley
GU16 7SR</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>United Kingdom</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Glaxo Operations UK Limited (Trading as
Glaxo Wellcome Operations), Harmire Road, Barnard Castle, County Durham, DL12
8DT<span style='color:black'>,</span> United Kingdom</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black;background:#D9D9D9'>Novartis
Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey
GU16 7SR, United Kingdom</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB
style='color:black;background:#D9D9D9'>Novartis Pharma GmbH, Roonstrasse 25,
90429 Nuremberg, Germany</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-BE>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=LT>Novartis
  Pharma Services Inc.</span></p>
  <p class=MsoNormal style='margin-right:-22.45pt'><span lang=LT>Tel: +370 5
  269 16 50</span></p>
  <p class=MsoNormal><span lang=FR-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Bulgaria EOOD</span></p>
  <p class=MsoNormal><span lang=BG>&#1058;&#1077;&#1083;:</span> +359 2 489 98
  28</p>
  <p class=MsoNormal><b><span lang=NO-BOK>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Novartis Pharma N.V.</span></p>
  <p class=MsoNormal><span lang=FR-BE>Tél/Tel: +32 2 246 16 11</span></p>
  <p class=MsoNormal><span lang=NO-BOK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>&#268;eská republika</span></b></p>
  <p class=MsoNormal><span lang=SV>Novartis s.r.o.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +420 225 775 111</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU>Magyarország</span></b></p>
  <p class=MsoNormal><span lang=HU>Novartis Hungária Kft.</span></p>
  <p class=MsoNormal><span lang=HU>Tel.: +36 1 457 65 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Danmark</b></p>
  <p class=MsoNormal>Novartis Healthcare A/S</p>
  <p class=MsoNormal>Tlf: +45 39 16 84 00</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=MT>Malta</span></b></p>
  <p class=MsoNormal><span lang=MT>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal><span lang=MT>Tel: +</span>356 <span lang=FR-CH>2122 2872</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49 911 273 0</span></p>
  <p class=MsoNormal><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>Novartis Pharma B.V.</span></p>
  <p class=MsoNormal><span lang=NL>Tel: +31 26 37 82 555</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal><span lang=ET>Tel: +372 </span><span lang=EN-GB>66 30 810</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal><span lang=NO-BOK>Novartis Norge AS</span></p>
  <p class=MsoNormal><span lang=NO-BOK>Tlf: +47 23 05 20 00</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=ET>Novartis (Hellas) A.E.B.E.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span><span lang=ET>: +30
  210 281 17 12</span></p>
  <p class=MsoNormal><span lang=ET>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-AT>Österreich</span></b></p>
  <p class=MsoNormal><span lang=DE-AT>Novartis Pharma GmbH</span></p>
  <p class=MsoNormal><span lang=DE-AT>Tel: +43 1 86 6570</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>España</span></b></p>
  <p class=MsoNormal><span lang=ES>Novartis Farmacéutica, S.A.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +34 93 306 42 00</span></p>
  <p class=MsoNormal><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>Novartis Poland Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=PL>Tel.: +48 22 375 4888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>Novartis Pharma S.A.S.</span></p>
  <p class=MsoNormal><span lang=FR>Tél: +33 1 55 47 66 00</span></p>
  <p class=MsoNormal><b><span lang=PL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=ES>Novartis Farma - Produtos Farmacêuticos,
  S.A.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 21 000 8600</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Hrvatska d.o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel. +385 1 6274 220</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b>România</b></p>
  <p class=MsoNormal style='text-autospace:none'>Novartis Pharma Services <span
  lang=EN-GB>Romania SRL</span></p>
  <p class=MsoNormal>Tel: +40 21 31299 01</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Ireland Limited</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1 260 12 55</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal><span lang=SL>Tel: +386 1 300 75 50</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS>Ísland</span></b></p>
  <p class=MsoNormal><span lang=IS>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Sími</span><span lang=IS>: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK>Slovenská republika</span></b></p>
  <p class=MsoNormal><span lang=SK>Novartis Slovakia s.r.o.</span></p>
  <p class=MsoNormal><span lang=SK>Tel: +421 2 5542 5439</span></p>
  <p class=MsoNormal><span lang=SK>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Novartis Farma S.p.A.</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +39 02 96 54 1</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=FI>Novartis Finland Oy</span></p>
  <p class=MsoNormal><span lang=FI>Puh/Tel: +358 </span><span lang=DE-CH>(0)10
  6133 200</span></p>
  <p class=MsoNormal><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=FR-CH>Novartis Pharma Services Inc.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +357 22 690 690</span></p>
  <p class=MsoNormal><b><span lang=EL>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>Novartis Sverige AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 8 732 32 00</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LV>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>SIA Novartis Baltics</span></p>
  <p class=MsoNormal><span lang=LV>Tel: +371 67 887 070</span></p>
  <p class=MsoNormal><span lang=FI>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Novartis Pharmaceuticals UK Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1276 698370</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>This
leaflet was last revised in</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency
(EMA) web site: </span><span lang=EN-GB>http://www.ema.europa.eu<span
style='color:blue'>/.</span></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The following
information is intended for healthcare professionals only:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b>1)      Before
diluting Arzerra</b></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>Check the<i> </i><span
lang=EN-GB>Arzerra concentrate<i> </i>for particulate matter and discolouration
prior to dilution. Ofatumumab should be a colourless to pale yellow solution.
Do not use the Arzerra concentrate if there is discolouration.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not shake
the ofatumumab vial for this inspection.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>2)      How to dilute the solution for infusion</span></b></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The <span lang=EN-GB>Arzerra</span>
concentrate must be diluted in sodium chloride 9&nbsp;mg/ml (0.9%) solution for
injection prior to administration, using aseptic technique.</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>300&nbsp;mg dose </span></b><span lang=EN-GB>- Use three
100&nbsp;mg/5&nbsp;ml vials (15&nbsp;ml total, 5&nbsp;ml per vial):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw and discard 15&nbsp;ml from a
1000&nbsp;ml bag of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw 5&nbsp;ml of ofatumumab from each of the
three 100&nbsp;mg vials and inject into the 1000&nbsp;ml bag;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not shake; mix diluted solution by gentle
inversion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>1000&nbsp;mg dose </span></b><span lang=EN-GB> Use one
1000&nbsp;mg/50&nbsp;ml vial (50&nbsp;ml total, 50&nbsp;ml per vial):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw and discard 50&nbsp;ml from a 1000 ml
bag of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw 50&nbsp;ml of ofatumumab from the
1000&nbsp;mg vial and inject into the 1000&nbsp;ml bag</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not shake; mix diluted solution by gentle
inversion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>2000&nbsp;mg dose </span></b><span lang=EN-GB> Use two
1000&nbsp;mg/50&nbsp;ml vials (100&nbsp;ml total, 50&nbsp;ml per vial):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw and discard 100&nbsp;ml from a 1000 ml
bag of sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Withdraw 50&nbsp;ml of ofatumumab from each of the
two 1000&nbsp;mg vials and inject into the 1000&nbsp;ml bag;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol;color:black'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not shake; mix diluted solution by gentle
inversion.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>3)      How to administer the diluted solution</span></b></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra must
not be administered as an intravenous push or bolus. Administer using an
intravenous infusion pump</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The infusion
must be completed within 24&nbsp;hours after preparation. Discard any unused
solution after this time.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Arzerra must
not be mixed with, or administered as an infusion with other medicinal products
or intravenous solutions. Flush line before and after ofatumumab administration
with sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection to avoid this.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB>Previously
untreated CLL and relapsed CLL:</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For the
first infusion, administer over 4.5 hours </span><span lang=EN-GB>(</span><span
lang=EN-GB>see section&nbsp;4.2</span><span lang=EN-GB> of the SmPC), </span><span
lang=EN-GB>through a peripheral line or indwelling catheter, according to the
schedule below:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If the first
infusion was completed without a severe adverse reaction, the remaining
infusions of 1000&nbsp;mg should be administered over 4&nbsp;hours (see
section&nbsp;4.2 of the SmPC), through a peripheral line or indwelling
catheter, according to the schedule below. If any infusion&#8209;related
adverse reactions are observed, infusion should be interrupted and restarted
when the patients condition is stable (see section&nbsp;4.2 of the SmPC).</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><u><span
lang=EN-GB>Infusion schedule</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width=236 rowspan=2 style='width:176.65pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Time after start of infusion (minutes)</span></p>
  </td>
  <td width=188 style='width:141.15pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion&nbsp;1</span></p>
  </td>
  <td width=195 style='width:146.55pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Subsequent infusions*</span></p>
  </td>
 </tr>
 <tr>
  <td width=188 style='width:141.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
  <td width=195 style='width:146.55pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0&#8209;30</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31&#8209;60</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61&#8209;90</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>91&#8209;120</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>121&#8209;150</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>151&#8209;180</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>300</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=236 valign=top style='width:176.65pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>180+</span></p>
  </td>
  <td width=188 valign=top style='width:141.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
  <td width=195 valign=top style='width:146.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>*If the
  previous infusion was completed without severe infusion&#8209;related ADRs.
  If any infusion&#8209;related ADRs are observed, infusion should be
  interrupted and restarted when the patients condition is stable (see </span><span
  lang=EN-GB>section&nbsp;4.2 of the SmPC</span><span lang=EN-GB>).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Refractory CLL:</u></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>For the first and second infusion, administer over 6.5&nbsp;hours
(see section&nbsp;4.2 of the SmPC), through a peripheral line or indwelling
catheter, according to the schedule below:</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>If the second infusion was completed without a severe adverse
reaction, the remaining infusions (3&#8209;12) should be administered over
4&nbsp;hours (see section 4.2 of the SmPC), through a peripheral line or
indwelling catheter, according to the schedule below. If any infusion&#8209;related
adverse reactions are observed, infusion should be interrupted and restarted
when the patients condition is stable (see section&nbsp;4.2 of the SmPC).</span></p>

<p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u><span lang=EN-GB>Infusion
schedule</span></u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=206 rowspan=2 style='width:154.25pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Time after start of infusion (minutes)</span></p>
  </td>
  <td width=180 style='width:134.7pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusions&nbsp;1 and 2</span></p>
  </td>
  <td width=179 style='width:134.6pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusions&nbsp;3* to 12</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 style='width:134.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
  <td width=179 style='width:134.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Infusion rate (ml/hour)</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0&#8209;30</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>12</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31&#8209; 60</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>25</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61&#8209;90</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>50</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>91&#8209;120</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>100</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>121+</span></p>
  </td>
  <td width=180 valign=top style='width:134.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>200</span></p>
  </td>
  <td width=179 valign=top style='width:134.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>400</span></p>
  </td>
 </tr>
 <tr>
  <td width=565 colspan=3 valign=top style='width:423.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>*If the
  second infusion was completed without severe infusion&#8209;related ADRs. If
  any infusion&#8209;related ADRs are observed, infusion should be interrupted
  and restarted when the patients condition is stable (see section&nbsp;4.2).</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused medicinal product or waste
material should be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
